<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1211" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1211/" /><meta name="ncbi_pagename" content="Lynch Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Lynch Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Lynch Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/04/12" /><meta name="citation_author" content="Wendy Kohlmann" /><meta name="citation_author" content="Stephen B Gruber" /><meta name="citation_pmid" content="20301390" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1211/" /><meta name="citation_keywords" content="HNPCC" /><meta name="citation_keywords" content="Hereditary Non-Polyposis Colon Cancer" /><meta name="citation_keywords" content="HNPCC" /><meta name="citation_keywords" content="Hereditary Non-Polyposis Colon Cancer" /><meta name="citation_keywords" content="DNA mismatch repair protein Mlh1" /><meta name="citation_keywords" content="DNA mismatch repair protein Msh2" /><meta name="citation_keywords" content="DNA mismatch repair protein Msh6" /><meta name="citation_keywords" content="Epithelial cell adhesion molecule" /><meta name="citation_keywords" content="Mismatch repair endonuclease PMS2" /><meta name="citation_keywords" content="EPCAM" /><meta name="citation_keywords" content="MLH1" /><meta name="citation_keywords" content="MSH2" /><meta name="citation_keywords" content="MSH6" /><meta name="citation_keywords" content="PMS2" /><meta name="citation_keywords" content="Lynch Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Lynch Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Wendy Kohlmann" /><meta name="DC.Contributor" content="Stephen B Gruber" /><meta name="DC.Date" content="2018/04/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1211/" /><meta name="description" content="Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen:" /><meta name="og:title" content="Lynch Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1211/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hnpcc/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1211/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE895FF8E040C5E10000000005990257.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1211_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1211_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/x-lpd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/lpi/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1211_"><span class="title" itemprop="name">Lynch Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: HNPCC, Hereditary Non-Polyposis Colon Cancer</div><p class="contrib-group"><span itemprop="author">Wendy Kohlmann</span>, MS and <span itemprop="author">Stephen B Gruber</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1211_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1211_ai__"><div class="contrib half_rhythm"><span itemprop="author">Wendy Kohlmann</span>, MS<div class="affiliation small">University of Utah Huntsman Cancer Institute<br />Salt Lake City, Utah<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hatu.ich@nnamlhok.ydnew" class="oemail">ude.hatu.ich@nnamlhok.ydnew</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Stephen B Gruber</span>, MD, PhD<div class="affiliation small">USC Norris Comprehensive Cancer Center<br />Los Angeles, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.csu@reburgs" class="oemail">ude.csu@reburgs</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 5, 2004</span>; Last Revision: <span itemprop="dateModified">April 12, 2018</span>.</p><p><em>Estimated reading time: 45 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hnpcc.Summary" itemprop="description"><h2 id="_hnpcc_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen:</p><ul><li class="half_rhythm"><div><i>CRC:</i> 52%-82% (mean age at diagnosis 44-61 years)</div></li><li class="half_rhythm"><div><i>Endometrial cancer in females:</i> 25%-60% (mean age at diagnosis 48-62 years)</div></li><li class="half_rhythm"><div><i>Gastric cancer:</i> 6%-13% (mean age at diagnosis 56 years)</div></li><li class="half_rhythm"><div><i>Ovarian cancer:</i> 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed &#x0003c; age 40 years).</div></li></ul><p>The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of Lynch syndrome is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, or <i>PMS2</i> or an <i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> For colon cancer, full colectomy with ileorectal anastomosis is recommended. Other tumors are managed as in the general population.</p><p><i>Prevention of primary manifestations:</i> Prophylactic hysterectomy and bilateral salpingo-oophorectomy can be considered after childbearing is completed. Prophylactic colectomy prior to the development of colon cancer is generally not recommended for individuals known to have Lynch syndrome because screening colonoscopy with polypectomy is an effective preventive measure.</p><p><i>Surveillance:</i> Colonoscopy with removal of precancerous polyps every one to two years beginning between age 20 and 25 years or two to five years before the earliest age of diagnosis in the family, whichever is earlier. The efficacy of surveillance for cancer of the endometrium, ovary, stomach, duodenum, distal small bowel, urinary tract, and central nervous system is unknown.</p><p><i>Agents/circumstances to avoid:</i> Cigarette smoking.</p><p><i>Evaluation of relatives at risk:</i> When a diagnosis of Lynch syndrome has been confirmed in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should be offered to first-degree relatives to identify those who would benefit from early surveillance and intervention. Although molecular genetic testing for Lynch syndrome is generally not recommended for at-risk individuals younger than age 18 years, a history of early cancers in the family may warrant predictive testing prior to age 18.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Lynch syndrome is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. The majority of individuals diagnosed with Lynch syndrome have inherited the condition from a parent. However, because of incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, variable age of cancer development, cancer risk reduction as a result of screening or prophylactic surgery, or early death, not all individuals with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the genes associated with Lynch syndrome have a parent who had cancer. Each child of an individual with Lynch syndrome has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant in the family is known.</p></div></div><div id="hnpcc.Diagnosis"><h2 id="_hnpcc_Diagnosis_">Diagnosis</h2><div id="hnpcc.Suggestive_Findings"><h3>Suggestive Findings</h3><p>A diagnosis of Lynch syndrome <b>should be suspected</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with:</p><ul><li class="half_rhythm"><div class="half_rhythm">A diagnosis of colorectal cancer (CRC) or endometrial cancer and one or more of the following*:</div><ul><li class="half_rhythm"><div>Colorectal or endometrial cancer diagnosed before age 50 years</div></li><li class="half_rhythm"><div>Synchronous or metachronous Lynch syndrome-related cancers (e.g., colorectal, endometrial, stomach, small intestinal, hepatobiliary, renal pelvic, ureteral)</div></li><li class="half_rhythm"><div>Colorectal tumor tissue with MSI-high histology (e.g., poor differentiation, tumor-infiltrating lymphocytes, Crohn's-like lymphocytic reaction, mucinous/signet-ring differentiation, medullary growth pattern)</div></li><li class="half_rhythm"><div>Microsatellite instability (MSI) testing showing that tumor tissue (e.g., colon, endometrial) is MSI-high (For information on MSI testing including advantages and disadvantages, click <a href="/books/NBK1211/bin/hnpcc-msi.pdf">here</a>.)</div></li><li class="half_rhythm"><div>Tumor tissue (e.g., colon, endometrial) immunohistochemistry (IHC) demonstrates loss of expression of one or more of the <a class="def" href="/books/n/gene/glossary/def-item/mismatch-repair/">mismatch repair</a> (MMR) <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> products: MSH2, MLH1, MSH6, and PMS2. (For information on advantages and disadvantages of IHC testing, click <a href="/books/NBK1211/bin/hnpcc-ihc.pdf">here</a>.)</div></li><li class="half_rhythm"><div>At least one <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> with any Lynch syndrome-related cancer diagnosed before age 50 years</div></li><li class="half_rhythm"><div>At least two first-degree relatives with any Lynch syndrome-related cancers regardless of age of cancer diagnosis</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">A family member with colorectal or endometrial cancer who meets one of the above criteria</div><div class="half_rhythm">Note: Molecular genetic testing ideally begins with a person who has had a Lynch syndrome-related cancer. However, in some families there may be no <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual who is alive or willing to be tested.</div></li><li class="half_rhythm"><div class="half_rhythm">A family member with a confirmed diagnosis of Lynch syndrome</div></li><li class="half_rhythm"><div class="half_rhythm">A greater-than-5% probability of having a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the genes listed in <a class="figpopup" href="/books/NBK1211/table/hnpcc.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="fighnpccTmoleculargenetictestingusedi" rid-ob="figobhnpccTmoleculargenetictestingusedi">Table 1</a> based on risk assessment models</div><div class="half_rhythm">Note: Several risk assessment models including PREMM<sub>1,2,6</sub> [<a class="bk_pop" href="#hnpcc.REF.kastrinos.2011.73">Kastrinos et al 2011</a>] and MMRPro [<a class="bk_pop" href="#hnpcc.REF.chen.2006.1479">Chen et al 2006</a>] predict the likelihood of identifying a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the genes listed in <a class="figpopup" href="/books/NBK1211/table/hnpcc.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="fighnpccTmoleculargenetictestingusedi" rid-ob="figobhnpccTmoleculargenetictestingusedi">Table 1</a>. Both models have good predictive value in a clinical and population-based setting when using a 5% threshold for testing [<a class="bk_pop" href="#hnpcc.REF.win.2013a.785">Win et al 2013a</a>, <a class="bk_pop" href="#hnpcc.REF.kastrinos.2015">Kastrinos et al 2015</a>].</div></li></ul><p>*Adapted from revised Bethesda Guidelines and National Comprehensive Cancer Network (NCCN) Guidelines; click <a href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#colorectal_screening" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a> (no-fee registration and log-in required).</p><p><b>Population screening strategies for Lynch syndrome.</b> Lynch syndrome screening guidelines for individuals with CRC have been developed by the NCCN; click <a href="https://www.nccn.org/professionals/physician_gls/default.aspx#colorectal_screening" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a> (no-fee registration and log-in required). The <a href="http://www.lynchscreening.net/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Lynch Syndrome Screening Network</a> was established to help develop best-practice approaches for screening individuals with Lynch syndrome-related cancers and to collect long-term data on the outcomes of these programs [<a class="bk_pop" href="#hnpcc.REF.mange.2015.421">Mange et al 2015</a>].</p><p>Screening approaches include:</p><ul><li class="half_rhythm"><div>Screen all CRC with MSI or IHC testing. This was shown to be a cost-effective approach for identifying individuals who should be offered <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for Lynch syndrome [<a class="bk_pop" href="#hnpcc.REF.egapp.2009.35">EGAPP 2009</a>, <a class="bk_pop" href="#hnpcc.REF.ladabaum.2011.69">Ladabaum et al 2011</a>]. (For information on advantages and disadvantages of IHC testing, click <a href="/books/NBK1211/bin/hnpcc-ihc.pdf">here</a>. For information on MSI testing including advantages and disadvantages, click <a href="/books/NBK1211/bin/hnpcc-msi.pdf">here</a>.)</div></li><li class="half_rhythm"><div>Screen all CRC and endometrial cancers with MSI or IHC testing [<a class="bk_pop" href="#hnpcc.REF.egapp.2009.35">EGAPP 2009</a>, <a class="bk_pop" href="#hnpcc.REF.mange.2015.421">Mange et al 2015</a>].</div></li><li class="half_rhythm"><div>Use age of onset and pathologic features to predict which individuals are more likely to have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> MMR <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#hnpcc.REF.rabban.2014.793">Rabban et al 2014</a>].</div></li></ul><p><b>Targeted <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> on tumor tissue</b> should be considered in individuals with MLH1/PMS2 loss of expression on IHC. Targeted testing includes the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Targeted analysis of BRAF <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Val600Glu</div><div class="half_rhythm">Note: (1) <i>BRAF</i> p.Val600Glu is not present in Lynch syndrome-associated colorectal tumors (see <a href="#hnpcc.Differential_Diagnosis">Differential Diagnosis</a>, <b>Sporadic colorectal cancer</b>). (2) <i>BRAF</i> pathogenic variants are not common in <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> endometrial cancers; thus, <i>BRAF</i> testing is not helpful in distinguishing endometrial cancers that are sporadic from those that are Lynch syndrome related.</div></li><li class="half_rhythm"><div class="half_rhythm">MLH1 promoter <a class="def" href="/books/n/gene/glossary/def-item/methylation-analysis/">methylation analysis</a> on tumor tissue</div><div class="half_rhythm">Note: Lynch syndrome-related cancers do not have hypermethylation of the <i>MLH1</i> promoter (see <a href="#hnpcc.Differential_Diagnosis">Differential Diagnosis</a>, <b>Sporadic colorectal cancer</b>).</div></li></ul></div><div id="hnpcc.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of Lynch syndrome <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the genes listed in <a class="figpopup" href="/books/NBK1211/table/hnpcc.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="fighnpccTmoleculargenetictestingusedi" rid-ob="figobhnpccTmoleculargenetictestingusedi">Table 1</a>.</p><p>Molecular genetic testing approaches can include a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><div id="hnpcc.Option_1_recommended"><h4>Option 1 (recommended)</h4><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, and <i>PMS2</i> as well as <i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> analysis (see <a class="figpopup" href="/books/NBK1211/table/hnpcc.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="fighnpccTmoleculargenetictestingusedi" rid-ob="figobhnpccTmoleculargenetictestingusedi">Table 1</a>) and other genes of interest (see <a href="#hnpcc.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of multigene panels vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p></div><div id="hnpcc.Option_2_not_often_recommended"><h4>Option 2 (not often recommended)</h4><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing. </b>IHC results on tumor tissue testing may show loss of expression of one or more of the MMR genes indicating that loss of function of a particular MMR gene is most likely (see <a class="figpopup" href="/books/NBK1211/table/hnpcc.T.summary_of_tumor_tissue_test_res/?report=objectonly" target="object" rid-figpopup="fighnpccTsummaryoftumortissuetestres" rid-ob="figobhnpccTsummaryoftumortissuetestres">Table 2</a>). However, this correlation is not 100% and testing of more than one gene may be necessary. Therefore, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> using a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> is often more cost effective than serial single-gene testing.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="hnpcc.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Lynch Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1211/table/hnpcc.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hnpcc.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of Lynch Syndrome Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr><tr><th headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3" id="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3" id="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MLH1</i></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%-95%</td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%-10%</td></tr><tr><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MSH2</i></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%&#x000a0;<sup>5</sup></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;80%</td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;20%</td></tr><tr><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MSH6</i></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7%-10%&#x000a0;<sup>7</sup></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;95%</td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;5%</td></tr><tr><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PMS2</i></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;5%&#x000a0;<sup>8,&#x000a0;9</sup></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 10</td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 10</td></tr><tr><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>EPCAM</i></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~1%-3%&#x000a0;<sup>11</sup></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 12</td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>12</sup></td></tr><tr><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>13</sup></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_1_3 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_1 hd_h_hnpcc.T.molecular_genetic_testing_used_i_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hnpcc.TF.1.1"><p class="no_margin">See <a href="/books/NBK1211/#hnpcc.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hnpcc.TF.1.2"><p class="no_margin">See <a href="#hnpcc.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hnpcc.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="hnpcc.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="hnpcc.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#hnpcc.REF.smith.2016.250">Smith et al [2016]</a></p></div></dd><dt>6. </dt><dd><div id="hnpcc.TF.1.6"><p class="no_margin">Constitutional inactivation of <i>MLH1</i> by <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a>, along with somatic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> of the functional <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, has been reported to be a rare cause of Lynch syndrome. Such cases are not detectable by either <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> analysis of <i>MLH1</i> (see <a href="#hnpcc.Molecular_Genetics">Molecular Genetics</a>).</p></div></dd><dt>7. </dt><dd><div id="hnpcc.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#hnpcc.REF.miyaki.1997.271">Miyaki et al [1997]</a>, <a class="bk_pop" href="#hnpcc.REF.berends.2002.26">Berends et al [2002]</a>, <a class="bk_pop" href="#hnpcc.REF.peltom_ki.2003.1174">Peltom&#x000e4;ki [2003]</a></p></div></dd><dt>8. </dt><dd><div id="hnpcc.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#hnpcc.REF.senter.2008.419">Senter et al [2008]</a></p></div></dd><dt>9. </dt><dd><div id="hnpcc.TF.1.9"><p class="no_margin">Due to the high level of homology between <i>PMS2</i> and pseudogenes, testing and interpretation of findings in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> is difficult. A laboratory that adheres to ACMG guidelines for analysis of <i>PMS2</i> and that has expertise in testing this gene should be selected when a <i>PMS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is suspected in a family [<a class="bk_pop" href="#hnpcc.REF.hegde.2014.101">Hegde et al 2014</a>].</p></div></dd><dt>10. </dt><dd><div id="hnpcc.TF.1.10"><p class="no_margin">Methods to sequence and identify large rearrangements in <i>PMS2</i> have been developed and improved over time, making it difficult to determine the proportion of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> detected by each method in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> population. Nearly 200 sequence variants and more than 100 large rearrangements in <i>PMS2</i> have been reported [<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PMS2%20" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Human Gene Mutation Database</a>]. Variants detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> appear to be more common; however, large rearrangements may comprise more than 40%-50% of pathogenic variants in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#hnpcc.REF.van_der_klift.2010.578">van der Klift et al 2010</a>, <a class="bk_pop" href="#hnpcc.REF.vaughn.2010.588">Vaughn et al 2010</a>, <a class="bk_pop" href="#hnpcc.REF.smith.2016.250">Smith et al 2016</a>].</p></div></dd><dt>11. </dt><dd><div id="hnpcc.TF.1.11"><p class="no_margin">Although <i>EPCAM</i> is not a <a class="def" href="/books/n/gene/glossary/def-item/mismatch-repair/">mismatch repair</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, recurrent <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> deletions of the 3' region result in silencing of the adjacent downstream <i>MSH2</i> by hypermethylation [<a class="bk_pop" href="#hnpcc.REF.niessen.2009.737">Niessen et al 2009</a>, <a class="bk_pop" href="#hnpcc.REF.goel.2011.869">Goel et al 2011</a>, <a class="bk_pop" href="#hnpcc.REF.kuiper.2011.407">Kuiper et al 2011</a>].</p></div></dd><dt>12. </dt><dd><div id="hnpcc.TF.1.12"><p class="no_margin">Germline deletions of <i>EPCAM</i> result in silencing of the adjacent <i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> by hypermethylation. The adjacent <i>MSH2</i> allele itself is not mutated (see <a href="#hnpcc.Molecular_Pathogenesis">Molecular Pathogenesis</a>). Sequence analysis of <i>EPCAM</i> is not appropriate for diagnosis of Lynch syndrome.</p></div></dd><dt>13. </dt><dd><div id="hnpcc.TF.1.13"><p class="no_margin">There are a few case reports of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>EXO1</i>, <i>MLH3</i>, <i>MSH3</i>, <i>PMS1</i>, or <i>TGFBR2</i> variants in some families with Lynch syndrome; the clinical significance (if any) of allelic variants in these genes in Lynch syndrome has not yet been determined [<a class="bk_pop" href="#hnpcc.REF.lu.1998.17">Lu et al 1998</a>, <a class="bk_pop" href="#hnpcc.REF.peltom_ki.2003.1174">Peltom&#x000e4;ki 2003</a>].</p></div></dd></dl></div></div></div><div id="hnpcc.T.summary_of_tumor_tissue_test_res" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Summary of Tumor Tissue Test Results, Interpretation, and Additional Tiered Testing Options</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1211/table/hnpcc.T.summary_of_tumor_tissue_test_res/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hnpcc.T.summary_of_tumor_tissue_test_res_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1" colspan="7" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Tumor Testing&#x000a0;<sup>1</sup></th><th id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="3" scope="col" colspan="1" headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" style="text-align:left;vertical-align:middle;">Plausible Etiologies</th><th id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="3" scope="col" colspan="1" headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" style="text-align:left;vertical-align:middle;">Additional Tiered Testing&#x000a0;Options&#x000a0;<sup>2</sup></th></tr><tr><th headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1" id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1" colspan="4" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Immunohistochemistry (IHC)</th><th headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;">MSI</th><th headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRAF</i> V600E&#x000a0;<sup>3</sup></th><th headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;"><i>MLH1</i> Promoter Methylation</th></tr><tr><th headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1" id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MLH1</i></th><th headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1" id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MSH2</i></th><th headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1" id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MSH6</i></th><th headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1" id="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PMS2</i></th></tr></thead><tbody><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MSS/<br />MSI-Low</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sporadic cancer</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MSI-High</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Germline MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> path var</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin"><i>MLH1</i> &#x00026; <i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd><dt>2.</dt><dd><p class="no_top_margin"><i>MSH6</i> &#x00026; possibly <i>PMS2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd></dl>
</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MSI-High</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Sporadic cancer</div></li><li class="half_rhythm"><div>Germline MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> path var</div></li></ul>
</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">IHC to guide <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing<br />OR
<dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin"><i>MLH1</i> &#x00026; <i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd><dt>2.</dt><dd><p class="no_top_margin"><i>MSH6</i> &#x00026; possibly <i>PMS2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd></dl>
</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Sporadic cancer</div></li><li class="half_rhythm"><div>Germline <i>MLH1</i> path var</div></li></ul>
</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin"><i>BRAF</i>&#x000a0;V600E&#x000a0;<sup>3</sup> &#x00026; <i>MLH1</i> promoter <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a></p></dd><dt>2.</dt><dd><p class="no_top_margin"><i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd></dl>
</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pos</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sporadic cancer</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neg</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pos</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Sporadic cancer</div></li><li class="half_rhythm"><div>Rarely, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>MLH1</i> path var</div></li><li class="half_rhythm"><div>Constitutional <i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/epimutation/">epimutation</a></div></li></ul>
</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>If no significant family history: none</div></li><li class="half_rhythm"><div>Significant family history &#x00026;/or early onset: <i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</div></li><li class="half_rhythm"><div>Early onset only: constitutional <i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/epimutation/">epimutation</a> testing</div></li></ul>
</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neg</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neg</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Germline <i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Germline <i>MSH2</i> path var</div></li><li class="half_rhythm"><div>Germline <i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a></div></li><li class="half_rhythm"><div>Rarely, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>MSH6</i> path var</div></li></ul>
</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin"><i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd><dt>2.</dt><dd><p class="no_top_margin"><i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> testing</p></dd><dt>3.</dt><dd><p class="no_top_margin"><i>MSH6</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd></dl>
</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Germline <i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Germline <i>PMS2</i> path var</div></li><li class="half_rhythm"><div>Germline <i>MLH1</i> path var</div></li></ul>
</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin"><i>PMS2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd><dt>2.</dt><dd><p class="no_top_margin"><i>MLH1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd></dl>
</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Germline <i>MSH2</i> path var</div></li><li class="half_rhythm"><div>Germline <i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a></div></li></ul>
</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin"><i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd><dt>2.</dt><dd><p class="no_top_margin"><i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> testing</p></dd></dl>
</td></tr><tr><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_1 hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Germline <i>MSH6</i> path var</div></li><li class="half_rhythm"><div>Germline <i>MSH2</i> path var</div></li><li class="half_rhythm"><div>Germline <i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a></div></li></ul>
</td><td headers="hd_h_hnpcc.T.summary_of_tumor_tissue_test_res_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin"><i>MSH6</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd><dt>2.</dt><dd><p class="no_top_margin"><i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> testing</p></dd><dt>3.</dt><dd><p class="no_top_margin"><i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> testing</p></dd></dl>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#hnpcc.REF9">NCCN [2016]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">Empty cells indicate either that testing was not done or that results may not influence testing strategy.</p></div></dd><dt></dt><dd><div><p class="no_margin">&#x02013; = absent staining of protein; + = normal staining of protein; MMR = <a class="def" href="/books/n/gene/glossary/def-item/mismatch-repair/">mismatch repair</a>; MSI = <a class="def" href="/books/n/gene/glossary/def-item/microsatellite/">microsatellite</a> instability; MSS = MSI-stable; Neg = negative; path var = <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; Pos = positive</p></div></dd><dt>1. </dt><dd><div id="hnpcc.TF.2.1"><p class="no_margin">Tumor testing strategies apply to colorectal and endometrial cancers. Limited data exist regarding the efficacy of tumor testing in other Lynch syndrome tumors.</p></div></dd><dt>2. </dt><dd><div id="hnpcc.TF.2.2"><p class="no_margin">For information on testing for <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants, see <a class="figpopup" href="/books/NBK1211/table/hnpcc.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="fighnpccTmoleculargenetictestingusedi" rid-ob="figobhnpccTmoleculargenetictestingusedi">Table 1</a>.</p></div></dd><dt>3. </dt><dd><div id="hnpcc.TF.2.3"><p class="no_margin">Testing is not appropriate for tumors other than colorectal cancer.</p></div></dd><dt>4. </dt><dd><div id="hnpcc.TF.2.4"><p class="no_margin">In the presence of a strong family history (i.e., Amsterdam criteria are met), additional testing may be warranted in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> or tumor testing in another <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member because of the possibility that the original tumor selected for testing was a <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> colorectal cancer.</p></div></dd></dl></div></div></div></div></div></div><div id="hnpcc.Clinical_Characteristics"><h2 id="_hnpcc_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hnpcc.Clinical_Description"><h3>Clinical Description</h3><p>Individuals with Lynch syndrome are at increased risk for colorectal cancer (CRC) and other cancers including cancers of the endometrium, ovary, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin (<a class="figpopup" href="/books/NBK1211/table/hnpcc.T.cancer_risks_by_gene_in_individu/?report=objectonly" target="object" rid-figpopup="fighnpccTcancerrisksbygeneinindividu" rid-ob="figobhnpccTcancerrisksbygeneinindividu">Table 3</a>).</p><div id="hnpcc.T.cancer_risks_by_gene_in_individu" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Cancer Risks by Gene in Individuals with Lynch Syndrome Age &#x02264;70 Years Compared to the General Population</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1211/table/hnpcc.T.cancer_risks_by_gene_in_individu/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hnpcc.T.cancer_risks_by_gene_in_individu_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" style="text-align:left;vertical-align:middle;">Cancer<br />Type</th><th id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" style="text-align:left;vertical-align:middle;">General<br />Population<br />Risk</th><th id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;"><i>MLH1</i> and <i>MSH2</i></th><th id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MSH6</i></th><th id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PMS2</i></th></tr><tr><th headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3" id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Risk</th><th headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3" id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mean Age<br />of Onset</th><th headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4" id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Risk</th><th headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5" id="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Risk</th></tr></thead><tbody><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Colorectal</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.5%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">M: 27%-74%<br />F: 22%-53%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">27-46 yrs</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">M: 22%<br />F: 10%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">M: 20%<br />F: 15%</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Endometrial</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.7%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14%-54%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">48-62 yrs</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16%-26%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15%</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gastric</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.2%-13%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">49-55 yrs</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">M: 6%<br />F: 22%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_4" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">6%</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ovarian</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.6%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4%-20%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">43-45 yrs</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Small bowel</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4%-12%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">49 yrs</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatobiliary tract</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.2%-4%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">54-57</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urinary tract</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.2%-25%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">52-60 yrs</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Brain</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-4%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~50 yrs</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sebaceous neoplasms</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-9%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not<br />reported</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pancreas</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.5%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.4%-4%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">63-65 yrs</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prostate</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.2%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%-30%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">59-60 yrs</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12.4%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%-18%</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_3 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">52 yrs</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_4 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_1_5 hd_h_hnpcc.T.cancer_risks_by_gene_in_individu_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#hnpcc.REF.senter.2008.419">Senter et al [2008]</a>, <a class="bk_pop" href="#hnpcc.REF.baglietto.2010.193">Baglietto et al [2010]</a>, <a class="bk_pop" href="#hnpcc.REF.bonadona.2011.2304">Bonadona et al [2011]</a>, <a class="bk_pop" href="#hnpcc.REF.giardiello.2014.1159">Giardiello et al [2014]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">F = female; M = male</p></div></dd></dl></div></div></div><p><b>Colorectal cancer.</b> The risk of colorectal cancer (CRC) associated with <i>MLH1</i> and <i>MHS2</i> pathogenic variants is significantly higher than the risk associated with <i>MSH6</i> or <i>PMS2</i> pathogenic variants. The mean ages at onset for CRC in individuals with <i>MSH6</i> and <i>PMS2</i> pathogenic variants are also older than for onset for CRC associated with <i>MLH1</i> and <i>MSH2</i> pathogenic variants, 54-63 years and 47-66 years respectively. However, up to 8% of CRCs in <i>PMS2</i> heterozygotes occur before age 30. Therefore, individuals with <i>MLH6</i> or <i>PMS2</i> pathogenic variants should follow the same CRC screening recommendations as <i>MLH1</i> and <i>MSH2</i> heterozygotes. A 2009 study of a Finnish cohort with high compliance with screening found no increase in mortality for individuals with Lynch syndrome compared to relatives without the Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, indicating that annual colonoscopy is effective for the prevention and detection of CRC [<a class="bk_pop" href="#hnpcc.REF.j_rvinen.2009.4793">J&#x000e4;rvinen et al 2009</a>].</p><p>Data on cancer risks for those with an <i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> is still limited, but <a class="bk_pop" href="#hnpcc.REF.kempers.2011.49">Kempers et al [2011]</a> reported on findings from 194 individuals with an <i>EPCAM</i> deletion. From this cohort they estimated a 75% (95% CI 65-86) cumulative incidence of CRC by age 70 years. The risk for CRC did not differ between those who had only a 3' deletion of <i>EPCAM</i> and those individuals with a deletion that encompassed <i>EPCAM</i> and <i>MSH2.</i> However, only those with an <i>EPCAM</i> deletion that includes <i>MSH2</i> are at an increased risk for extracolonic cancers [<a class="bk_pop" href="#hnpcc.REF.kempers.2011.49">Kempers et al 2011</a>, <a class="bk_pop" href="#hnpcc.REF.tutlewska.2013.9">Tutlewska et al 2013</a>].</p><p>Tumors that are MSI-H, either due to <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> causes or an underlying <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/mismatch-repair/">mismatch repair</a> (MMR) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, tend to have a better prognosis than MSS tumors [<a class="bk_pop" href="#hnpcc.REF.kawakami.2015.30">Kawakami et al 2015</a>].</p><p><b>Endometrial cancer.</b> The risk for women with <i>EPCAM</i> deletions that encompass <i>MSH2</i> is similar to that for individuals with <i>MSH2</i> pathogenic variants.</p><p>Among females with Lynch syndrome who develop both CRC and endometrial cancer, approximately 50% present first with endometrial cancer [<a class="bk_pop" href="#hnpcc.REF.lu.2005.569">Lu et al 2005</a>]. The risk for subsequent endometrial cancer to females with Lynch syndrome presenting first with CRC has been estimated at 26% within ten years of the initial CRC diagnosis [<a class="bk_pop" href="#hnpcc.REF.obermair.2010.2678">Obermair et al 2010</a>].</p><p>Overall, a survival advantage similar to that in Lynch syndrome-related CRC has been reported in Lynch syndrome-related endometrial cancers [<a class="bk_pop" href="#hnpcc.REF.maxwell.2001.417">Maxwell et al 2001</a>].</p><p><b>Gastric cancer.</b> Intestinal-type adenocarcinoma, the most commonly reported pathology of Lynch syndrome-related gastric cancers [<a class="bk_pop" href="#hnpcc.REF.aarnio.1997.551">Aarnio et al 1997</a>], differs histologically from the diffuse gastric cancer that is most commonly seen in <a href="/books/n/gene/hgc/">hereditary diffuse gastric cancer</a> caused by pathogenic variants in <i>CDH1</i> [<a class="bk_pop" href="#hnpcc.REF.guilford.1999.249">Guilford et al 1999</a>]. However, <a class="bk_pop" href="#hnpcc.REF.capelle.2010.487">Capelle et al [2010]</a> reported that up to 20% of Lynch syndrome-related gastric cancers may be the diffuse type. The risk for gastric cancer is higher in individuals with Lynch syndrome who reside in countries with a high incidence of <i>H pylori</i> infection [<a class="bk_pop" href="#hnpcc.REF.park.2000.2994">Park et al 2000</a>].</p><p><b>Ovarian cancer</b> risk to females with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>MLH1</i> or <i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been found to be 4%-20%. The mean age of diagnosis of Lynch syndrome-associated ovarian cancer has been reported at between age 43 and 45 years, although diagnosis at very young ages has been reported. Approximately 30% of Lynch syndrome-associated ovarian cancers are diagnosed before age 35 years [<a class="bk_pop" href="#hnpcc.REF.watson.2008.444">Watson et al 2008</a>].</p><p>The distribution of pathology types is similar to that seen in <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> ovarian cancers. Borderline ovarian tumors do not appear to be associated with Lynch syndrome [<a class="bk_pop" href="#hnpcc.REF.watson.2001.223">Watson et al 2001</a>].</p><p><b>Small bowel cancer.</b> The duodenum and jejunum are the most common sites for small bowel cancers, with approximately 50% in reach of upper endoscopy [<a class="bk_pop" href="#hnpcc.REF.schulmann.2005.590">Schulmann et al 2005</a>]. The majority of small bowel cancers are adenocarcinomas [<a class="bk_pop" href="#hnpcc.REF.rodriguezbigas.1998.240">Rodriguez-Bigas et al 1998</a>, <a class="bk_pop" href="#hnpcc.REF.schulmann.2005.590">Schulmann et al 2005</a>].</p><p><b>Urinary tract cancers.</b> The urinary tract cancers most commonly associated with Lynch syndrome are transitional carcinomas of the ureter and renal pelvis.</p><p>Bladder cancer risk is also likely increased in individuals with Lynch syndrome. A study of Dutch individuals with Lynch syndrome demonstrated a relative risk for bladder cancer of 4.4 for males and 2.2 for females; the majority of tumor tissue available for testing was MSI-H and/or had loss of protein expression by IHC [<a class="bk_pop" href="#hnpcc.REF.van_der_post.2010.464">van der Post et al 2010</a>].</p><p>Individuals with Lynch syndrome and a prior diagnosis of CRC were also at increased risk for subsequent bladder cancer (7.22, 95% CI=4.08-10.99) and other urinary tract cancers (kidney, renal pelvis, and ureter) (12.54, 95% CI 7.97-17.94) [<a class="bk_pop" href="#hnpcc.REF.win.b">Win et al 2013b</a>].</p><p>Risk estimates for urinary tract cancers vary significantly based on gender and the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> involved.</p><p><b>Brain tumors.</b> The most common type of central nervous system tumor is glioblastoma [<a class="bk_pop" href="#hnpcc.REF.hamilton.1995.839">Hamilton et al 1995</a>, <a class="bk_pop" href="#hnpcc.REF.wimmer.2008.105">Wimmer &#x00026; Etzler 2008</a>]. The brain tumors associated with pathogenic variants in an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> are typically MSI-H [<a class="bk_pop" href="#hnpcc.REF.hamilton.1995.839">Hamilton et al 1995</a>, <a class="bk_pop" href="#hnpcc.REF.suzui.1998.126">Suzui et al 1998</a>].</p><p><b>Sebaceous neoplasms</b> described in individuals with Lynch syndrome include: sebaceous adenomas, sebaceous epitheliomas, sebaceous carcinomas, and keratoacanthomas. Sebaceous neoplasms associated with Lynch syndrome are typically MSI-H [<a class="bk_pop" href="#hnpcc.REF.entius.2000.1784">Entius et al 2000</a>, <a class="bk_pop" href="#hnpcc.REF.machin.2002.415">Machin et al 2002</a>]. Data on the frequency of sebaceous neoplasms in individuals with Lynch syndrome are limited. Studies have found that between 1% and 9% of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have a sebaceous neoplasm [<a class="bk_pop" href="#hnpcc.REF.ponti.2006.2302">Ponti et al 2006</a>, <a class="bk_pop" href="#hnpcc.REF.south.2008.277">South et al 2008</a>].</p><div id="hnpcc.Other_Cancers"><h4>Other Cancers</h4><p>Other Lynch syndrome-related cancers that have characteristic features have been reported.</p><p><b>Pancreatic cancer.</b> A study by <a class="bk_pop" href="#hnpcc.REF.kastrinos.2009.1790">Kastrinos et al [2009]</a> based on reported family history found an 8.6-fold increased risk up to age 70 years for pancreatic cancer [<a class="bk_pop" href="#hnpcc.REF.kastrinos.2009.1790">Kastrinos et al 2009</a>]. A prospective study that followed 446 individuals with an MMR <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and 1,029 relatives for a median of five years found an increased risk for pancreatic cancer (SIR, 10.68; 95% CI 2.68-47.70), and no increased risk for individuals without a pathogenic variant [<a class="bk_pop" href="#hnpcc.REF.win.2012.958">Win et al 2012</a>]. However, other studies have not demonstrated an increased risk [<a class="bk_pop" href="#hnpcc.REF.barrow.2009.141">Barrow et al 2009</a>]. Lynch syndrome has been found to be a rare cause of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pancreatic cancer [<a class="bk_pop" href="#hnpcc.REF.gargiulo.2009.547">Gargiulo et al 2009</a>].</p><p><b>Prostate cancer.</b> Several studies have demonstrated an association with prostate cancer, with the increase in risk ranging from two- to fivefold [<a class="bk_pop" href="#hnpcc.REF.raymond.2013b.1713">Raymond et al 2013b</a>, <a class="bk_pop" href="#hnpcc.REF.haraldsdottir.2014.553">Haraldsdottir et al 2014</a>, <a class="bk_pop" href="#hnpcc.REF.ryan.2014.437">Ryan et al 2014</a>]. <a class="bk_pop" href="#hnpcc.REF.raymond.2013b.1713">Raymond et al [2013b]</a> found that the risk for prostate cancer was increased for males with an MMR <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> prior to age 60 [<a class="bk_pop" href="#hnpcc.REF.raymond.2013b.1713">Raymond et al 2013b</a>], whereas an analysis by <a class="bk_pop" href="#hnpcc.REF.haraldsdottir.2014.553">Haraldsdottir et al [2014]</a> did not find earlier age of onset or a more aggressive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in the prostate cancers occurring in individuals with an MMR pathogenic variant. <a class="bk_pop" href="#hnpcc.REF.pritchard.2016.443">Pritchard et al [2016]</a> identified a pathogenic variant in an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in four (0.5%) of 692 men with metastatic prostate cancer.</p><p><b>Breast cancer.</b> The relationship between breast cancer and Lynch syndrome is unresolved. A systematic review evaluated 21 studies; 13 did not demonstrate an increased risk for breast cancer in individuals with Lynch syndrome and eight showed an increased risk [<a class="bk_pop" href="#hnpcc.REF.win.b">Win et al 2013b</a>]. To date, breast cancer risk has only been evaluated in one prospective study. Individuals with an MMR <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> were found to have a standard incidence ratio for breast cancer of 3.95 (95% CI 1.59-8.13), and the median age of breast cancer diagnosis was 56 years. Tumor tissue IHC in 51% of breast cancers in individuals with an MMR pathogenic variant demonstrated loss of expression for the MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> with the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant. Due to the high frequency of breast cancer in the general population, the presence of <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> breast cancers complicates analysis of the association with Lynch syndrome.</p><p><b>Additional cancer risks.</b> Several other cancer types have been reported to occur in individuals with Lynch syndrome. In some cases, MSI and/or IHC testing of tumor tissue demonstrated concordance between the extracolonic cancer and the molecular diagnosis of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual. While such findings suggest that the underlying presence of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> contributed to the development of the cancer, data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</p><ul><li class="half_rhythm"><div>Several types of sarcomas have been reported in individuals with an MMR <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, including fibrous histiocytomas, rhabdomyosarcomas, leiomyosarcoma, and liposarcoma [<a class="bk_pop" href="#hnpcc.REF.sijmons.2000.353">Sijmons et al 2000</a>, <a class="bk_pop" href="#hnpcc.REF.den_bakker.2003.297">den Bakker et al 2003</a>, <a class="bk_pop" href="#hnpcc.REF.nilbert.2009.209">Nilbert et al 2009</a>]. <a class="bk_pop" href="#hnpcc.REF.nilbert.2009.209">Nilbert et al [2009]</a> determined that six of eight sarcomas in individuals with Lynch syndrome exhibited defective MMR, suggesting that sarcomas may also be part of the spectrum of Lynch syndrome tumors. Due to the rarity of sarcomas it may be difficult to determine the magnitude of risk associated with Lynch syndrome.</div></li><li class="half_rhythm"><div>Adrenocortical carcinoma (ACC) has also been reported in families with Lynch syndrome. The most extensive study of this association, performed through a hereditary cancer clinic at the University of Michigan, found that two (1.7%) of 114 individuals presenting with ACC had a family history consistent with Lynch syndrome and had an MMR <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified. This association was further evaluated by case review of 135 individuals with pathogenic MMR variants, which identified two (1.4%) individuals who also had ACC [<a class="bk_pop" href="#hnpcc.REF.raymond.2013a.3012">Raymond et al 2013a</a>].</div></li></ul></div><div id="hnpcc.Lynch_Syndrome_Variants"><h4>Lynch Syndrome Variants</h4><p><b>Muir-Torre syndrome</b> is a historical term used to describe individuals presenting with the combination of sebaceous neoplasms of the skin and one or more internal malignancies, commonly those seen in Lynch syndrome. The types of sebaceous skin neoplasms described include: sebaceous adenomas, sebaceous epitheliomas, sebaceous carcinomas, and keratoacanthomas [<a class="bk_pop" href="#hnpcc.REF.misago.2000.155">Misago &#x00026; Narisawa 2000</a>].</p><p><b>Turcot syndrome</b> is a historical term used to describe individuals presenting with CRC or colorectal adenomas in addition to tumors of the central nervous system. The clinical presentation varies from numerous colonic polyps to a single polyp or colorectal cancer. Turcot syndrome is usually caused by either a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the MMR genes associated with Lynch syndrome or an <i>APC</i> pathogenic variant (see <a href="#hnpcc.Differential_Diagnosis">Differential Diagnosis</a> and <a href="/books/n/gene/fap/"><i>APC</i>-Associated Polyposis Conditions</a>).</p><p><b>Constitutional MMR deficiency (CMMRD).</b> Rare individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for pathogenic variants in <i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, and <i>PMS2</i> have been reported. Affected individuals often have onset of colon or small bowel cancer prior to the second decade of life. One third of children with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been reported to have more than ten polyps. Hematologic cancer, brain tumors, and caf&#x000e9; au lait macules have also been reported [<a class="bk_pop" href="#hnpcc.REF.wimmer.2008.105">Wimmer &#x00026; Etzler 2008</a>, <a class="bk_pop" href="#hnpcc.REF.durno.2010.2449">Durno et al 2010</a>, <a class="bk_pop" href="#hnpcc.REF.bakry.2014.987">Bakry et al 2014</a>]. The cutaneous <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may be remarkably similar to that seen in <a href="/books/n/gene/nf1/">neurofibromatosis type I</a> as nearly all will have caf&#x000e9; au lait macules [<a class="bk_pop" href="#hnpcc.REF.wimmer.2012">Wimmer 2012</a>, <a class="bk_pop" href="#hnpcc.REF.bakry.2014.987">Bakry et al 2014</a>]. Features in the family history that increase suspicion of CMMRD:</p><ul><li class="half_rhythm"><div>Family history of Lynch syndrome</div></li><li class="half_rhythm"><div>Consanguineous parents</div></li><li class="half_rhythm"><div>At least one parent with clinical findings of Lynch syndrome</div></li></ul><p>However, this diagnosis should not be excluded if the family history is negative, as a significant number of children with a confirmed diagnosis of CMMRD will not have a family history consistent with Lynch syndrome. <a class="bk_pop" href="#hnpcc.REF.bakry.2014.987">Bakry et al [2014]</a> reported that a history of Lynch syndrome cancers was rarely noted in the family members of children with CMMRD.</p></div></div><div id="hnpcc.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>Cancer risks vary among the genes associated with Lynch syndrome.</p><p><b><i>MSH2</i>.</b> Heterozygosity for an <i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is associated with the greatest risk for extracolonic cancers.</p><p><i>MSH2</i> pathogenic variants have been reported more commonly than a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the other three MMR genes in individuals with the Muir-Torre variant of Lynch syndrome [<a class="bk_pop" href="#hnpcc.REF.south.2008.277">South et al 2008</a>].</p><p><b><i>MSH6.</i></b> Heterozygosity for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MSH6</i> is associated with MSI-low tumors. The colorectal cancers in families with an <i>MSH6</i> pathogenic variant may be later in onset and more distally located than the cancers in families with Lynch syndrome resulting from a pathogenic variant in one of the other MMR genes; endometrial cancer is commonly observed in females with an <i>MSH6</i> pathogenic variant [<a class="bk_pop" href="#hnpcc.REF.wu.1999.1291">Wu et al 1999</a>, <a class="bk_pop" href="#hnpcc.REF.berends.2002.26">Berends et al 2002</a>]. Slightly lower risks for colorectal cancer and higher risks for endometrial cancer have been reported in families with an <i>MSH6</i> pathogenic variant than in families with an <i>MLH1</i> or <i>MSH2</i> pathogenic variant [<a class="bk_pop" href="#hnpcc.REF.berends.2002.26">Berends et al 2002</a>, <a class="bk_pop" href="#hnpcc.REF.baglietto.2010.193">Baglietto et al 2010</a>].</p><p><b><i>PMS2.</i></b> Heterozygosity for a <i>PMS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is associated with the lowest risk (25%-32% risk) for any Lynch syndrome-related cancer [<a class="bk_pop" href="#hnpcc.REF.senter.2008.419">Senter et al 2008</a>]. However, while the overall risk of CRC is lower, age of onset may still be early. A review of 234 <i>PMS2</i> pathogenic variant carriers found that 8% were diagnosed before age 30 [<a class="bk_pop" href="#hnpcc.REF.goodenberger.2016.13">Goodenberger et al 2016</a>].</p><p><b><i>EPCAM.</i></b> Deletions of <i>EPCAM</i> that result in epigenetic silencing of <i>MSH2</i> are associated with a significantly increased risk for colorectal cancer. <a class="bk_pop" href="#hnpcc.REF.kempers.2011.49">Kempers et al [2011]</a> reported a low risk for endometrial cancer in those with deletions of <i>EPCAM</i> compared to pathogenic variants in an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div><div id="hnpcc.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b><i>EPCAM.</i></b> The risk for extracolonic cancers is dependent on the size of the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>. 3' <i>EPCAM</i> deletions have been shown to confer a lower risk for extracolonic cancers, whereas deletions that extend into <i>MSH2</i> confer extracolonic cancer risks similar to intragenic <i>MSH2</i> pathogenic variants [<a class="bk_pop" href="#hnpcc.REF.tutlewska.2013.9">Tutlewska et al 2013</a>].</p></div><div id="hnpcc.Penetrance"><h3>Penetrance</h3><p>Penetrance of CRCs and extracolonic cancers associated with pathogenic variants in an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or <i>EPCAM</i> is less than 100% (see <a class="figpopup" href="/books/NBK1211/table/hnpcc.T.cancer_risks_by_gene_in_individu/?report=objectonly" target="object" rid-figpopup="fighnpccTcancerrisksbygeneinindividu" rid-ob="figobhnpccTcancerrisksbygeneinindividu">Table 3</a>). Therefore, some individuals with a cancer-predisposing <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an MMR gene or <i>EPCAM</i> may never develop cancer.</p></div><div id="hnpcc.Nomenclature"><h3>Nomenclature</h3><p>Lynch syndrome has also been called hereditary non-polyposis colorectal cancer (HNPCC). Clinicians and researchers working in the area of hereditary colorectal cancer have suggested returning to the use of the original name, Lynch syndrome, to include individuals and families with confirmed pathogenic variants in an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or <i>EPCAM</i>.</p></div><div id="hnpcc.Prevalence"><h3>Prevalence</h3><p>Lynch syndrome accounts for approximately 1%-3% of CRCs and 0.8%-1.4% of endometrial cancers [<a class="bk_pop" href="#hnpcc.REF.kowalski.1997.219">Kowalski et al 1997</a>, <a class="bk_pop" href="#hnpcc.REF.chadwick.2001.461">Chadwick et al 2001</a>, <a class="bk_pop" href="#hnpcc.REF.cunningham.2001.780">Cunningham et al 2001</a>].</p><p>The population prevalence of Lynch syndrome has been estimated at 1:440 [<a class="bk_pop" href="#hnpcc.REF.chen.2006.1479">Chen et al 2006</a>].</p></div></div><div id="hnpcc.Genetically_Related_Allelic_Disord"><h2 id="_hnpcc_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, and <i>PMS2.</i></p><p>Pathogenic variants in <i>EPCAM</i> cause the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder diarrhea 5 with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> tufting enteropathy (OMIM <a href="https://omim.org/entry/613217" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613217</a>).</p><p>Sporadic tumors (including colorectal and endometrial cancers) found to have <a class="def" href="/books/n/gene/glossary/def-item/mismatch-repair/">mismatch repair</a> (MMR) deficiency (based on MSI and/or IHC analysis) may be due to <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> somatic pathogenic variants in <i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, or <i>PMS2</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>; predisposition to these tumors is not heritable [<a class="bk_pop" href="#hnpcc.REF.haraldsdottir.2014.553">Haraldsdottir et al 2014</a>].</p></div><div id="hnpcc.Differential_Diagnosis"><h2 id="_hnpcc_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Attenuated</b>
<a href="/books/n/gene/fap/"><b>familial adenomatous polyposis</b></a>
<b>(AFAP).</b> This milder presentation of FAP, also caused by pathogenic variants in <i>APC</i>, is characterized by fewer polyps and later age of onset than classic FAP. In AFAP, typically fewer than 100 polyps are observed. Polyps of the gastric fundus and duodenum also occur; however, many of the extracolonic manifestations commonly observed in FAP (e.g., epidermal cysts, dental abnormalities, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> hypertrophy of retinal pigmented epithelium, desmoid tumors) may be absent in AFAP. Polyps and colorectal cancers associated with AFAP do not usually exhibit MSI. AFAP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p><b>Turcot syndrome</b> is a historical term used to describe individuals presenting with colorectal cancer (CRC) or colorectal adenomas in addition to tumors of the central nervous system. Individuals with an <i>APC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> typically have more polyps; however, a significant overlap in polyp number occurs between individuals with Turcot syndrome caused by an <i>APC</i> pathogenic variant and those with Turcot syndrome caused by a pathogenic variant in a <a class="def" href="/books/n/gene/glossary/def-item/mismatch-repair/">mismatch repair</a> (MMR) <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#hnpcc.REF.hamilton.1995.839">Hamilton et al 1995</a>]. The pathology of the CNS tumor can help distinguish between the underlying genetic causes: <i>APC</i> pathogenic variants are more commonly associated with medulloblastoma; pathogenic variants in MMR genes are more commonly associated with glioblastoma.</p><p><a href="/books/n/gene/maps/"><b><i>MUTYH</i>-associated polyposis</b></a><b>.</b> Biallelic pathogenic variants in <i>MUTYH</i> (<i>MYH</i>) have been described in individuals with multiple adenomatous polyps. Pathogenic variants in <i>MUTYH</i> have been identified in: (1) approximately 30% of individuals with 15-100 polyps; (2) a small portion of individuals with a classic FAP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> who have no identifiable <i>APC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; and (3) individuals with a family history of CRC in the absence of multiple polyps. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p><b><i>MSH3</i>-related susceptibility to polyposis and CRC</b> (OMIM <a href="https://omim.org/entry/600887" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">600887</a>). Biallelic <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>MSH3</i> pathogenic variants have been rarely reported in families with multiple adenomatous polyps and early-onset CRC. To date only a few individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>MSH3</i> pathogenic variants have been described; thus, risks for additional tumors or cancers have not been well established. Other features reported in those with biallelic pathogenic variants include duodenal polyps, intraductal papilloma of the breast, astrocytoma, thyroid adenoma, and uterine leiomyoma.</p><p><b><i>NTHL1</i>-related susceptibility to polyposis and CRC</b> (OMIM <a href="https://omim.org/entry/616415" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616415</a>). Biallelic <i>NTHL1</i> pathogenic variants have also been identified in families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> polyposis and an increased risk for CRC. The number of polyps reported in these individuals has ranged from one to greater than 50. The age range of developing CRC is 40 to 65 years. To date only a few families with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>NTHL1</i> pathogenic variants have been described, and specific risks for other cancers have not been determined. However, multiple tumors including breast cancer, meningiomas, bladder cancer, endometrial cancer, and basal cell carcinoma have been reported in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#hnpcc.REF.weren.2018.135">Weren et al 2018</a>].</p><p><b><i>POLE</i>-related susceptibility to CRC</b> (OMIM <a href="https://omim.org/entry/615083" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615083</a>). Individuals with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>POLE</i> pathogenic variants are at increased risk for CRC. These individuals may present with few to numerous polyps. Several additional types of cancer including endometrial, ovarian, ureter, gastric, and astrocytoma have been reported in families of individuals with a <i>POLE</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Endometrial cancers related to germline <i>POLE</i> pathogenic variants may be either MSS or MSI-high [<a class="bk_pop" href="#hnpcc.REF.billingsley.2015.386">Billingsley et al 2015</a>]. To date, most information about <i>POLE</i> is based on a single recurrent pathogenic variant, p.Leu424Val, and it is unknown if other pathogenic variants may be associated with different risks or phenotypes.</p><p><b><i>POLD1-</i>related susceptibility to CRC</b> (OMIM <a href="https://omim.org/entry/174761" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">174761</a>). Pathogenic variants in <i>POLD1</i> have been found to be a very rare cause of hereditary CRC. Germline pathogenic variants in <i>POLD1</i> have been reported in individuals with either a few or multiple polyps. Endometrial cancer and astrocytoma have also been reported in these families [<a class="bk_pop" href="#hnpcc.REF.bellido.2016.325">Bellido et al 2016</a>].</p><p><a href="/books/n/gene/li-fraumeni/"><b>Li-Fraumeni syndrome</b></a><b>.</b> CRC and other GI cancers are increasingly recognized as a component of Li-Fraumeni syndrome, which is caused by pathogenic variants in <i>TP53</i> [<a class="bk_pop" href="#hnpcc.REF.mork.2015.3544">Mork et al 2015</a>, <a class="bk_pop" href="#hnpcc.REF.yurgelun.2017.1086">Yurgelun et al 2017</a>]. Consideration of Li-Fraumeni syndrome should be included in the evaluation of individuals with early-onset CRC.</p><p><b>Hamartomatous polyp syndromes.</b> Several <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> conditions associated with an increased risk for hamartomatous polyps and CRC can usually be distinguished by their extracolonic manifestations as well as hamartomatous rather than adenomatous pathology:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/jps/">Juvenile polyposis syndrome</a> (JPS), caused by pathogenic variants in <i>SMADA4</i> and <i>BMPR1A</i></div></li><li class="half_rhythm"><div><a href="/books/n/gene/pjs/">Peutz-Jeghers syndrome</a> (PJS), caused by pathogenic variants in <i>STK11</i></div></li><li class="half_rhythm"><div><a href="/books/n/gene/phts/"><i>PTEN</i> hamartomatous syndromes</a> (including Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome), caused by pathogenic variants in <i>PTEN</i></div></li></ul><p><a href="/books/n/gene/hgc/"><b>Hereditary diffuse gastric cancer</b></a><b>.</b> The gastric cancers, caused by <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of <i>CDH1</i>, are typically adenocarcinomas. Hereditary diffuse gastric cancer is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p><a href="/books/n/gene/brca1/"><b><i>BRCA1/BRCA2</i> hereditary breast/ovarian syndrome</b></a> should be considered when evaluating an individual with a family history of cancer that includes ovarian cancer. Hereditary breast and ovarian cancer syndrome caused by <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>BRCA1</i> or <i>BRCA2</i> is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p><b>Moderate-risk CRC predisposition genes.</b> Many families exhibit a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> predisposition to CRC that is not explained by Lynch syndrome or the other high-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> conditions described. Analysis of families with multiple individuals with MSS CRC have shown an increased risk for CRC, though typically lower than the risks seen in individuals with pathogenic variants in <i>MSH2</i> and <i>MLH1</i>. Also, these families do not generally exhibit an increased risk for other Lynch syndrome-associated cancers [<a class="bk_pop" href="#hnpcc.REF.abdelrahman.2005.1542">Abdel-Rahman et al 2005</a>, <a class="bk_pop" href="#hnpcc.REF.lindor.2005.1979">Lindor et al 2005</a>, <a class="bk_pop" href="#hnpcc.REF.muellerkoch.2005.1733">Mueller-Koch et al 2005</a>]. These studies have suggested that other genetic factors, outside of the MMR pathway, are likely contributing to risk.</p><div id="hnpcc.T.genes_associated_with_moderate_r" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Genes Associated with Moderate Risk for CRC</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1211/table/hnpcc.T.genes_associated_with_moderate_r/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hnpcc.T.genes_associated_with_moderate_r_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gene</th><th id="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pathogenic Variant</th><th id="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRC Risk</th></tr></thead><tbody><tr><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>MUTYH</i></td><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pathogenic variant carriers</td><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.5-2-fold</td></tr><tr><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>APC</i></td><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">c.3920T&#x0003e;A</td><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2-fold</td></tr><tr><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>CHEK2</i></td><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">c.1100del</td><td headers="hd_h_hnpcc.T.genes_associated_with_moderate_r_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2-fold&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#hnpcc.REF9">NCCN [2016]</a></p></div></dd><dt>1. </dt><dd><div id="hnpcc.TF.4.1"><p class="no_margin">Additional increased risk for breast cancer</p></div></dd></dl></div></div></div><p><b>Sporadic</b>
<b>colorectal cancer</b></p><ul><li class="half_rhythm"><div><b><i>BRAF</i>-related.</b>
<i>BRAF</i> pathogenic variants, the most common being c.1799T&#x0003e;A (p.Val600Glu or V600E) <a href="/nuccore/NM_004333.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004333.4</a>, occur in 15% of CRCs. <i>BRAF</i> pathogenic variants are thought to be rare in Lynch syndrome-related cancers and, thus, in general the presence of a <i>BRAF</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> rules out the diagnosis of Lynch syndrome [<a class="bk_pop" href="#hnpcc.REF.bellizzi.2009.405">Bellizzi &#x00026; Frankel 2009</a>, <a class="bk_pop" href="#hnpcc.REF.bouzourene.2010.167">Bouzourene et al 2010</a>].</div></li><li class="half_rhythm"><div><b>Somatic <i>MLH1</i> promoter <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a>.</b> The majority of MSI is caused by somatic methylation of the <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a> of <i>MLH1</i> that silences <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression in the tumor tissue; thus, the finding of <i>MLH1</i> promoter methylation can often help eliminate the diagnosis of Lynch syndrome in individuals without additional suggestive features.</div></li></ul></div><div id="hnpcc.Management"><h2 id="_hnpcc_Management_">Management</h2><div id="hnpcc.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Lynch syndrome, the evaluations summarized in <a href="#hnpcc.Surveillance">Surveillance</a> are recommended, as well as consultation with a clinical geneticist and/or genetic counselor.</p></div><div id="hnpcc.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Management of colon cancer in a person with Lynch syndrome.</b> If colon cancer is detected, full colectomy with ileorectal anastomosis is recommended rather than a segmental/partial colonic resection because of the high risk for metachronous cancers. A meta-analysis of six studies including a total of 871 individuals found that based on an average of 91 months' follow up, the rate of metachronous cancers was 23% among those individuals who had a segmental colectomy, compared to 6% among individuals who had a colectomy (colectomy defined as subtotal or colectomy with ileosigmoid anastomosis) [<a class="bk_pop" href="#hnpcc.REF.anele.2017.528">Anele et al 2017</a>].</p><p>Population-based approaches for screening newly diagnosed individuals with CRC for Lynch syndrome generally rely on analysis of tumor tissue from the surgical resection specimen, but this will not provide information about the diagnosis of Lynch syndrome in time to make decisions about segmental/partial colectomy versus colectomy. For individuals presenting with CRC before age 50 and/or who have a strong family history, proceeding directly to genetic testing could be considered in order to have information about possible hereditary diagnoses in time for surgical planning.</p><p>The other tumors seen in Lynch syndrome are managed as in the general population.</p></div><div id="hnpcc.Prevention_of_Primary_Manifestatio"><h3>Prevention of Primary Manifestations</h3><p>Prophylactic hysterectomy and bilateral salpingo-oophorectomy can be considered after childbearing is completed.</p><p>Because screening colonoscopy with polypectomy is an effective preventive measure for colorectal cancer, prophylactic colectomy (removal of the colon prior to the development of cancer) is generally not recommended for individuals with Lynch syndrome.</p><p>Aspirin therapy has been shown to decrease the risk for CRC in individuals with Lynch syndrome (see <a href="#hnpcc.Therapies_Under_Investigation">Therapies Under Investigation</a>).</p></div><div id="hnpcc.Surveillance"><h3>Surveillance</h3><p><b>Colorectal cancer (CRC).</b> Colonoscopy with removal of precancerous polyps should be performed every one to two years beginning between age 20 and 25 years or two to five years before the earliest diagnosis in the family, whichever is earlier, for all individuals with Lynch syndrome. Regular colonoscopy with removal of precancerous polyps reduces the incidence of CRC in individuals with Lynch syndrome.</p><p>Colonoscopy is recommended rather than flexible sigmoidoscopy because of the predominance of proximal colon cancers in Lynch syndrome.</p><p><b>Endometrial cancer.</b> Endometrial cancer surveillance is less well established than that for colon cancer.</p><p>Educate females about the symptoms of endometrial cancers (e.g., abnormal uterine bleeding, postmenopausal bleeding), because many endometrial cancers can be diagnosed at early stages on the basis of symptoms.</p><p>Endometrial biopsy every one to two years can be considered, but to date data do not support that such additional testing improves early detection or outcomes [<a class="bk_pop" href="#hnpcc.REF9">NCCN 2016</a>].</p><p>Studies on the effectiveness of transvaginal ultrasound examination and endometrial biopsy have had conflicting results:</p><ul><li class="half_rhythm"><div>In a study of the use of transvaginal ultrasound examination to screen for endometrial cancer, no cancers were detected; however, two cancers were detected on the basis of symptoms manifest during the course of the study [<a class="bk_pop" href="#hnpcc.REF.doveedwin.2002.1708">Dove-Edwin et al 2002</a>].</div></li><li class="half_rhythm"><div>A report from a Finnish cohort found that endometrial sampling and transvaginal ultrasound every two to three years resulted in the diagnosis of early-stage cancers. However, because endometrial cancer often presents with symptoms at an early stage, it was not clear that the screening improved detection [<a class="bk_pop" href="#hnpcc.REF.j_rvinen.2009.4793">J&#x000e4;rvinen et al 2009</a>].</div></li></ul><p><b>Ovarian cancer.</b> No specific ovarian cancer screening trials have been conducted in females with Lynch syndrome.</p><p>Educate women about the symptoms that may be associated with ovarian cancer (e.g., pelvic or abdominal pain, bloating, increased abdominal girth, difficulty eating, early satiety, urinary frequency or urgency).</p><p>Screening for ovarian cancer using serum CA-125 and transvaginal ultrasound examination has not been effective in other high-risk populations such as females with a <i>BRCA1</i> or <i>BRCA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#hnpcc.REF.evans.2009.593">Evans et al 2009</a>], but may be recommended at the clinician's discretion.</p><p><b>Gastric and duodenal cancers.</b> Over time, screening recommendations for gastric and duodenal cancers have varied. Studies have not supported that screening improves early detection or outcomes of these cancers, but because the stomach and duodenum are the most common extracolonic non-gynecologic cancer in Lynch syndrome, periodic upper endoscopy exams have been included in guidelines. Upper endoscopy can be considered, particularly for individuals with a family history of gastric cancer and those of Asian ancestry, every three to five years beginning between age 30 and 35 years [<a class="bk_pop" href="#hnpcc.REF9">NCCN 2016</a>]. Note: Biopsies should be evaluated for <i>H pylori</i> infections so that appropriate treatment can be given as needed [<a class="bk_pop" href="#hnpcc.REF9">NCCN 2016</a>].</p><p>Data regarding the effectiveness of upper endoscopy examination for the early detection of gastric cancer in Lynch syndrome are limited.</p><ul><li class="half_rhythm"><div>One study suggested no benefit from this screening for gastric cancer because of the lack of identifiable precursor lesions [<a class="bk_pop" href="#hnpcc.REF.renkonensinisalo.2002.574">Renkonen-Sinisalo et al 2002</a>].</div></li><li class="half_rhythm"><div>A study looking at gastric cancer risk in a Dutch study suggested that the level of risk is sufficient to warrant screening; however, since 87% of the cancers occurred after age 45 years, it may be most cost effective to initiate screening at age 45 years [<a class="bk_pop" href="#hnpcc.REF.capelle.2010.487">Capelle et al 2010</a>].</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#hnpcc.REF.schulmann.2005.590">Schulmann et al [2005]</a> found that approximately 50% of the small bowel cancers in a cohort with Lynch syndrome were located in the duodenum, suggesting that upper endoscopy may be useful for screening. However, no trials to determine the efficacy of upper endoscopy for screening for duodenal cancers have been conducted.</div></li></ul><p><b>Distal small bowel.</b> Data are limited regarding screening for cancer in the distal small bowel. Capsule endoscopy and small bowel enterography are available for evaluating the small bowel, but at this time, there is no recommendation for routine use of these approaches for small bowel screening, although they may be helpful for evaluating symptomatic individuals.</p><p><b>Urinary tract.</b> NCCN recommends consideration of annual urine analysis beginning between age 30 and 35 years [<a class="bk_pop" href="#hnpcc.REF9">NCCN 2016</a>].</p><p><b>Central nervous system.</b> Consider an annual physical exam that includes a neurologic evaluation beginning at age 25 to 30 years. At this time, there is no recommendation for routine imaging to screen for brain tumors.</p><p><b>Other cancers.</b> At this time, no specific screening recommendations for other Lynch syndrome-associated cancers exist. Individuals should be encouraged to follow other general population screening guidelines and to seek prompt medical attention for changes in health or persistent symptoms. As noted previously, individuals with Lynch syndrome may be at increased risk for other cancers such as breast and prostate. However, it is not clear that these risks warrant screening above and beyond what is currently recommended for general population screening for these cancers. If there is a family history of early onset of other cancer types, cancer screening recommendations should be adjusted to begin screening at an earlier age.</p></div><div id="hnpcc.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Cigarette smoking increases the risk for CRC in Lynch syndrome [<a class="bk_pop" href="#hnpcc.REF.pande.2010.1331">Pande et al 2010</a>].</p></div><div id="hnpcc.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of all first-degree relatives (parents, sibs, and children) of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><p>Early recognition of cancers associated with Lynch syndrome may allow for timely intervention and improved final outcome.</p><ul><li class="half_rhythm"><div>Sibs should be considered at risk even if the parents have not had cancer because most Lynch syndrome results from an inherited (not <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If clinical history and family history cannot identify the parent from whom the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> inherited the Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should be offered to both parents to determine which has the pathogenic variant.</div></li></ul><p>In general, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for Lynch syndrome is not recommended for at-risk individuals younger than age 18 years. However, predictive testing should be considered if there is a history of early-onset cancer in the family. For unaffected individuals with a Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, screening should begin between age 20 and 25 years, or two to five years earlier than the earliest diagnosis in the family [<a class="bk_pop" href="#hnpcc.REF9">NCCN 2016</a>]. Therefore, a history of early cancers in the family may also warrant testing prior to age 18.</p><p>See <a href="#hnpcc.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hnpcc.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Ideally cancer screening exams would be planned around a pregnancy. An <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> female would be encouraged to be current on her cancer screening before attempting to become pregnant. If an affected female is diagnosed with cancer during pregnancy, she should be counseled about cancer treatment options and their potential implications for the fetus.</p></div><div id="hnpcc.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><div id="hnpcc.Chromoendoscopy_and_Intensive_Colo"><h4>Chromoendoscopy and Intensive Colonoscopy</h4><p>A 2008 study compared the effectiveness of chromoendoscopy and intensive colonoscopy inspection in early detection of polyps in persons with Lynch syndrome. Following standard colonoscopy, study participants were randomized to receive a second colonoscopy with chromoendoscopy or a second colonoscopy with careful inspection. This study found that although polyps are frequently missed during standard colonoscopy, no difference was observed between the number of additional polyps detected by chromoendoscopy and by the careful second-look colonoscopy [<a class="bk_pop" href="#hnpcc.REF.stoffel.2008.470">Stoffel et al 2008</a>].</p><p>A more recent study randomized 61 people with Lynch syndrome to standard white light colonoscopy or colonoscopy performed with virtual chromoendoscopy. The virtual chromoendoscopy (also called I-SCAN) is a filter feature that helps highlight subtle changes in the lining, providing a similar effect to traditional chromoendoscopy. Participants then had a repeat scope using the other method. The authors found that virtual chromoendoscopy after standard colonoscopy detected 15 missed polyps, while standard colonoscopy after virtual chromoendoscopy found only two missed polyps [<a class="bk_pop" href="#hnpcc.REF.bisschops.2017.342">Bisschops et al 2017</a>]. There will likely continue to be improvements in colonoscopy imaging, which will improve detection of polyps and screening outcomes for individuals with Lynch syndrome [<a class="bk_pop" href="#hnpcc.REF.h_neburg.2009.316">H&#x000fc;neburg et al 2009</a>, <a class="bk_pop" href="#hnpcc.REF.rahmi.2015.288">Rahmi et al 2015</a>].</p></div><div id="hnpcc.Chemoprevention"><h4>Chemoprevention</h4><p>Use of aspirin can be considered to reduce CRC risk. The Colorectal/Adenoma/Carcinoma Prevention Programme 2 (CAPP2) was a four-arm, randomized trial comparing placebo versus 600 mg/day aspirin and placebo versus resistant starch (Novelose) 30 g/day among 1,071 individuals with Lynch syndrome. At a mean follow up of 29 months, neither aspirin nor starch had an effect on CRC risk [<a class="bk_pop" href="#hnpcc.REF.burn.2008.2567">Burn et al 2008</a>]. However, subsequent analysis of the data with a mean follow up of 55.7 months found a 63% reduction in CRC risk (HR 0.41, 95% CI 0.19-0.86; p=0.02) [<a class="bk_pop" href="#hnpcc.REF.burn.2011.2081">Burn et al 2011</a>].</p><p>While data specifically on the use of aspirin in individuals with Lynch syndrome is limited to the data from the CAPP2 study, several other studies have demonstrated the same effect of aspirin on <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> CRC [<a class="bk_pop" href="#hnpcc.REF.rothwell.2011.31">Rothwell et al 2011</a>]. Based on the combined experience several consensus statements and expert reviews including NCCN, the Mallorca guidelines, and the US Multi-Society Task Force on CRC suggest that aspirin can be considered, taking into account an individual's personal health and comorbidities, in the management of individuals with Lynch syndrome [<a class="bk_pop" href="#hnpcc.REF.vasen.2013.812">Vasen et al 2013</a>, <a class="bk_pop" href="#hnpcc.REF.giardiello.2014.1159">Giardiello et al 2014</a>, <a class="bk_pop" href="#hnpcc.REF9">NCCN 2016</a>]. The CAPP2 study used a dose of 600 mg/day, which is much higher than the dose of 75 mg/day that was found to be effective for reducing the risk for sporadic CRC. The CAPP3 study is currently under way with the goal of identifying the minimum dose of aspirin for reducing CRC risk in individuals.</p><p>Epidemiologic studies have found that use of oral contraceptives for more than one year is associated with significant reduction in endometrial cancer risk (HR 0.39, 95% CI 0.23 to 0.64) [<a class="bk_pop" href="#hnpcc.REF.dashti.2015.61">Dashti et al 2015</a>]. To date there are no prospective trials evaluating the impact of oral contraceptives on endometrial cancer risk. One study has demonstrated reduced endometrial proliferation, in women with Lynch syndrome after a three-month course of oral contraceptives [<a class="bk_pop" href="#hnpcc.REF.lu.2013.774">Lu et al 2013</a>]. At this time oral contraceptives are not included in recommendations for women with Lynch syndrome, but they are commonly used for managing routine gynecologic issues and for family planning. Data support that oral contraceptives will likely confer benefits to women with Lynch syndrome similar to those in the general population.</p><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div></div><div id="hnpcc.Genetic_Counseling"><h2 id="_hnpcc_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hnpcc.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Lynch syndrome is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="hnpcc.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The majority of individuals diagnosed with Lynch syndrome inherited a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from a parent who may or may not have had cancer.</div></li><li class="half_rhythm"><div>A parent <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may not have had cancer because of incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, variable age of cancer development, cancer risk reduction resulting from screening or prophylactic surgery, or early death.</div></li><li class="half_rhythm"><div>If clinical and family history cannot identify the parent from whom the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> inherited the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should be offered to both parents to determine which one has the pathogenic variant identified in the proband.</div></li><li class="half_rhythm"><div>In the rare event that the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is not detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband. The precise <i>de novo</i> pathogenic variant rate for Lynch syndrome is unknown but estimated to be extremely low [<a class="bk_pop" href="#hnpcc.REF.bisgaard.2003.56">Bisgaard &#x00026; Bernstein 2003</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are at a 50% risk of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Molecular genetic testing for the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> Lynch syndrome-related variant should be offered to all sibs.</div></li><li class="half_rhythm"><div>Even if the parents have not had cancer, sibs should still be considered at risk and offered <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> because most Lynch syndrome-related pathogenic variants are inherited, not <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with Lynch syndrome has a 50% chance of inheriting the Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on their relationship to the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. Family history or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can help determine whether maternal or paternal relatives are at risk.</p></div><div id="hnpcc.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hnpcc.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Specific risk issues.</b> Several factors can hinder the diagnosis of Lynch syndrome based on family history. Screening and removal of precancerous polyps and prophylactic surgery may prevent colon or endometrial cancer in some at-risk relatives; some who died young from other causes may never have developed cancer.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with Lynch syndrome has the pathogenic variant or clinical evidence of Lynch syndrome, it is possible that the proband has a <i>de novo</i> pathogenic variant. However, a <i>de novo</i> pathogenic variant is thought to be rare, and non-medical explanations, including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption, could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>Genetic cancer risk assessment and counseling.</b> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, see <a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</a> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p><p><b>Predictive testing</b> (i.e., testing of asymptomatic at-risk individuals)</p><ul><li class="half_rhythm"><div>Predictive testing for at-risk relatives is possible once the Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</div></li><li class="half_rhythm"><div>Potential consequences of such testing (including, but not limited to, socioeconomic changes and the need for long-term follow up and evaluation arrangements for individuals with a positive test result) as well as the capabilities and limitations of predictive testing should be discussed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> prior to testing.</div></li></ul><p><b>Predictive testing in minors</b> (i.e., testing of asymptomatic at-risk individuals younger than age 18 years)</p><ul><li class="half_rhythm"><div>In general, genetic testing for Lynch syndrome is not recommended for at-risk individuals younger than age 18 years. However, predictive testing should be considered if there is a history of early-onset cancer in the family. In unaffected individuals with a Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, screening is recommended beginnning at age 20 to 25 years, or two to five years prior to the earliest diagnosis in the family [<a class="bk_pop" href="#hnpcc.REF9">NCCN 2016</a>]. Therefore, a history of early cancers in the family may also warrant testing prior to age 18.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hnpcc.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the Lynch syndrome-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="hnpcc.Resources"><h2 id="_hnpcc_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA)</b></div><div><a href="http://www.cgaicc.com" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cgaicc.com</a></div></li><li class="half_rhythm"><div><b>Hereditary Colon Cancer Takes Guts</b></div><div><a href="http://www.hcctakesguts.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hcctakesguts.org</a></div></li><li class="half_rhythm"><div><b>Lynch Syndrome International</b></div><div>P.O. Box 5456</div><div>Vacaville CA 95688</div><div><b>Phone:</b> 707-689-5089</div><div><b>Email:</b> info@lynchcancers.com</div><div><a href="http://www.lynchcancers.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Lynch Syndrome International</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Lynch%20syndrome&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Lynch syndrome</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute (NCI)</b></div><div>6116 Executive Boulevard</div><div>Suite 300</div><div>Bethesda MD 20892-8322</div><div><b>Phone:</b> 800-422-6237 (toll-free)</div><div><b>Email:</b> cancergovstaff@mail.nih.gov</div><div><a href="http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/HealthProfessional/page1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Genetics of Colorectal Cancer (PDQ&#x000ae;)</a></div></li><li class="half_rhythm"><div><b>American Cancer Society (ACS)</b></div><div>250 Williams Street Northwest</div><div>Atlanta GA 30303</div><div><b>Phone:</b> 800-227-2345 (toll-free 24/7); 866-228-4327 (toll-free 24/7 TTY)</div><div><a href="http://www.cancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancer.org</a></div></li><li class="half_rhythm"><div><b>C3: Colorectal Cancer Coalition</b></div><div>1414 Prince Street</div><div>Suite 204</div><div>Alexandria VA 22314</div><div><b>Phone:</b> 877-427-2111 (toll-free); 703-548-1225</div><div><b>Fax:</b> 202-315-3871</div><div><b>Email:</b> info@fightcolorectalcancer.org</div><div><a href="http://fightcolorectalcancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fightcolorectalcancer.org</a></div></li><li class="half_rhythm"><div><b>Colon Cancer Alliance (CCA)</b></div><div>1200 G Street Northwest</div><div>Suite 800</div><div>Washington DC 20005</div><div><b>Phone:</b> 877-422-2030 (Toll-free Helpline); 202-434-8980</div><div><b>Fax:</b> 866-304-9075 (toll-free)</div><div><a href="http://www.ccalliance.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ccalliance.org</a></div></li><li class="half_rhythm"><div><b>Prospective Registry of MultiPlex Testing (PROMPT)</b></div><div><i>PROMPT is an online research registry for patients and families who have undergone multiplex genetic testing and were found to have a genetic variation which may be linked to an increased risk of having cancer.</i></div><div><a href="https://connect.patientcrossroads.org/?org=prompt" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PROMPT</a></div></li></ul></div><div id="hnpcc.Molecular_Genetics"><h2 id="_hnpcc_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hnpcc.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Lynch Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1211/table/hnpcc.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hnpcc.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hnpcc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hnpcc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hnpcc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hnpcc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hnpcc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hnpcc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hnpcc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4072" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>EPCAM</i></a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4072" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p21</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P16422" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epithelial cell adhesion molecule</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/EPCAM" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EPCAM homepage - Colon cancer gene variant databases</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=EPCAM" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EPCAM</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=EPCAM[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EPCAM</a></td></tr><tr><td headers="hd_b_hnpcc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4292" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MLH1</i></a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4292" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3p22<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P40692" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA mismatch repair protein Mlh1</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/MLH1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MLH1 homepage - Colon cancer gene variant databases</a><br /><a href="https://lovd.nl/MLH1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MLH1 @ ZAC-GGM</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MLH1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MLH1</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MLH1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MLH1</a></td></tr><tr><td headers="hd_b_hnpcc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4436" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MSH2</i></a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4436" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p21-p16</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P43246" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA mismatch repair protein Msh2</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/MSH2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MSH2 homepage - Colon cancer gene variant databases</a><br /><a href="http://www.med.mun.ca/mmrvariants/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mismatch Repair (MMR) Genes Variant Database (MSH2)</a><br /><a href="https://lovd.nl/MSH2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MSH2 @ ZAC-GGM</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MSH2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MSH2</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MSH2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MSH2</a></td></tr><tr><td headers="hd_b_hnpcc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2956" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MSH6</i></a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2956" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p16<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P52701" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DNA mismatch repair protein Msh6</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/MSH6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MSH6 homepage - Colon cancer gene variant databases</a><br /><a href="http://www.med.mun.ca/mmrvariants/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mismatch Repair (MMR) Genes Variant Database (MSH6)</a><br /><a href="https://lovd.nl/MSH6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MSH6 @ ZAC-GGM</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MSH6" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MSH6</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MSH6[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MSH6</a></td></tr><tr><td headers="hd_b_hnpcc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5395" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PMS2</i></a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5395" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7p22<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P54278" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mismatch repair endonuclease PMS2</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/PMS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PMS2 @ LOVD</a><br /><a href="http://www.med.mun.ca/mmrvariants/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mismatch Repair (MMR) Genes Variant Database (PMS2)</a><br /><a href="https://lovd.nl/PMS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PMS2 @ ZAC-GGM</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PMS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PMS2</a></td><td headers="hd_b_hnpcc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PMS2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PMS2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hnpcc.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hnpcc.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Lynch Syndrome (<a href="/omim/114500,120435,120436,158320,185535,276300,600259,600678,609309,609310,613244" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1211/table/hnpcc.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hnpcc.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/114500" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">114500</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLORECTAL CANCER; CRC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120435" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120435</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LYNCH SYNDROME I</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120436" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120436</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DNA MISMATCH REPAIR PROTEIN MLH1; MLH1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/158320" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">158320</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUIR-TORRE SYNDROME; MRTES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/185535" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">185535</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPITHELIAL CELLULAR ADHESION MOLECULE; EPCAM</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/276300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">276300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MISMATCH REPAIR CANCER SYNDROME; MMRCS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600259" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600259</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PMS1 HOMOLOG 2, MISMATCH REPAIR SYSTEM COMPONENT; PMS2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600678" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600678</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MutS HOMOLOG 6; MSH6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609309" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609309</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MutS HOMOLOG 2; MSH2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609310" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609310</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613244" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613244</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 8; HNPCC8</td></tr></tbody></table></div></div><div id="hnpcc.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Lynch syndrome is caused by pathogenic variants in genes involved with the <a class="def" href="/books/n/gene/glossary/def-item/mismatch-repair/">mismatch repair</a> (MMR) pathway. This pathway functions to identify and remove single-nucleotide mismatches or insertions and <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> loops. Pathogenic variants in four of the MMR genes can cause Lynch syndrome [<a class="bk_pop" href="#hnpcc.REF.peltom_ki.2003.1174">Peltom&#x000e4;ki 2003</a>]. The functions of the MMR genes can be disrupted by <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, truncating variants, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, large deletions, or <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> rearrangements. In addition, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> deletions within <i>EPCAM</i>, which is not an MMR <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, can disrupt the MMR pathway by <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> the adjacent MMR gene <i>MSH2</i>, even though <i>MSH2</i> itself has not been mutated.</p><div id="hnpcc.EPCAM"><h4><i>EPCAM</i></h4><p><b>Gene structure.</b>
<i>EPCAM</i> comprises nine exons encoding a protein of 314 amino acids. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1211/#hnpcc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Deletions involving the transcription termination signal of <i>EPCAM</i> are causative in 1% to 2.8% of families with Lynch syndrome. Other <i>EPCAM</i> pathogenic variants that do not affect the transcription termination signal cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> tufting enteropathy [<a class="bk_pop" href="#hnpcc.REF.sivagnanam.2010.222">Sivagnanam et al 2010</a>] (see <a href="#hnpcc.Genetically_Related_Allelic_Disord">Genetically Related Disorders</a>).</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>EPCAM</i> expression varies in tissues. High levels of expression were found in colorectal stem cells, while low levels of expression were detected in leukocytes [<a class="bk_pop" href="#hnpcc.REF.ligtenberg.2009.112">Ligtenberg et al 2009</a>]. Little is known about <i>EPCAM</i> expression in most other tissues predisposed to Lynch syndrome-related cancers.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>EPCAM</i> deletions are thought to arise from Alu-mediated <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> events [<a class="bk_pop" href="#hnpcc.REF.kuiper.2011.407">Kuiper et al 2011</a>]. Elimination of the <i>EPCAM</i> transcription termination signal results in transcription continuing into <i>MSH2</i> and silencing of the <i>MSH2</i> promoter by <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a>. Through this mechanism the <i>MSH2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration with the <i>EPCAM</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> becomes inactivated in the tissues in which <i>EPCAM</i> is expressed, while the other <i>MSH2</i> allele is unaffected. These deletions are transmitted in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner, as are <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> variants in genes involved in MMR [<a class="bk_pop" href="#hnpcc.REF.ligtenberg.2009.112">Ligtenberg et al 2009</a>].</p></div><div id="hnpcc.MLH1"><h4><i>MLH1</i></h4><p><b>Gene structure.</b>
<i>MLH1</i> is 57,357 kb in length, with 19 coding exons encoding a protein of 756 amino acids. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1211/#hnpcc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 200 different pathogenic variants have been reported in <i>MLH1</i> [<a class="bk_pop" href="#hnpcc.REF.peltom_ki.2003.1174">Peltom&#x000e4;ki 2003</a>, <a class="bk_pop" href="#hnpcc.REF.peltom_ki.2004.269">Peltom&#x000e4;ki &#x00026; Vasen 2004</a>]; see <a href="/books/NBK1211/#hnpcc.molgen.TA">Table A</a>. Deletions account for 5%-10% of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>MLH1</i> pathogenic variants.</p><p>Constitutional inactivation of <i>MLH1</i> by <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a>, along with somatic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> of the functional <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, has been reported as a rare cause of Lynch syndrome (~0.6%) [<a class="bk_pop" href="#hnpcc.REF.niessen.2009.737">Niessen et al 2009</a>]. These individuals have silencing of one <i>MLH1</i> allele, throughout their tissues, due to methylation of the promoter and a Lynch syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Most of such cases are <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> (i.e., a single occurrence in a family), but a few families with inherited hypermethylation have been reported [<a class="bk_pop" href="#hnpcc.REF.goel.2011.869">Goel et al 2011</a>]. <i>MLH1</i> promoter methylation is not detectable by either <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> analysis of <i>MLH1</i>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> DNA MMR protein Mlh1 dimerizes with the product of <i>PMS2</i> (PMS1 protein homolog 2) to coordinate the binding of other proteins involved with MMR including the helicases, the protein encoded by <i>EXO1</i>, proliferating cell nuclear antigen (PCNA), single-stranded-DNA binding-protein (RPA), and DNA polymerases [<a class="bk_pop" href="#hnpcc.REF.peltom_ki.2003.1174">Peltom&#x000e4;ki 2003</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>MLH1</i> acts in a recessive manner at the cellular level where there is an absence of functional Mlh1 protein in the tumor cells. This results from inactivation of both <i>MLH1</i> alleles in the tumor, which often occurs as a result of an <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> variant or silencing of the <i>MLH1</i> promoter by hypermethylation.</p></div><div id="hnpcc.MSH2"><h4><i>MSH2</i></h4><p><b>Gene structure.</b>
<i>MSH2</i> comprises 16 exons encoding a protein of 934 amino acids. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1211/#hnpcc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 170 pathogenic variants have been identified in <i>MSH2</i> [<a class="bk_pop" href="#hnpcc.REF.peltom_ki.2003.1174">Peltom&#x000e4;ki 2003</a>, <a class="bk_pop" href="#hnpcc.REF.peltom_ki.2004.269">Peltom&#x000e4;ki &#x00026; Vasen 2004</a>]. The higher proportion of Alu repeats may contribute to the higher rate of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> rearrangements in <i>MSH2</i> than in <i>MLH1</i> [<a class="bk_pop" href="#hnpcc.REF.van_der_klift.2005.123">van der Klift et al 2005</a>]. At least 20% of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>MSH2</i> pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or multiexon deletions.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> DNA MMR protein MSH2, the protein encoded by <i>MSH2</i>, forms a heterodimer with either DNA MMR protein MSH6 or MSH3 and functions to identify mismatches. A sliding clamp model has been suggested to describe the structure of the heterodimer. Mismatches in the DNA are thought to be detected as the clamp slides along the DNA [<a class="bk_pop" href="#hnpcc.REF.fishel.1993.1027">Fishel et al 1993</a>, <a class="bk_pop" href="#hnpcc.REF.gruber.2003.137">Gruber &#x00026; Kohlmann 2003</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>MSH2</i> acts in a recessive manner at the cellular level where there is an absence of functional Msh2 protein in the tumor cells. This results from inactivation of both <i>MSH2</i> alleles in the tumor, which often occurs by the mechanism of <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a>. <i>MSH2</i> promoter <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> has been shown to be the <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> event that silences the normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in individuals with an <i>MSH2-</i>inactivating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Of note, this is not a common cause of <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> colon cancer.</p></div><div id="hnpcc.MSH6"><h4><i>MSH6</i></h4><p><b>Gene structure.</b>
<i>MSH6</i> comprises ten exons encoding a protein of 1,360 amino acids. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1211/#hnpcc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 30 pathogenic variants have been identified in <i>MSH6</i> [<a class="bk_pop" href="#hnpcc.REF.peltom_ki.2004.269">Peltom&#x000e4;ki &#x00026; Vasen 2004</a>]. Exon or multiexon deletions are a rare cause of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>MSH6</i> pathogenic variants.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The protein encoded by <i>MSH6</i>, DNA MMR protein MSH6, forms a heterodimer with DNA MMR protein MSH2 and functions to identify mismatches by a sliding clamp model [<a class="bk_pop" href="#hnpcc.REF.fishel.1993.1027">Fishel et al 1993</a>, <a class="bk_pop" href="#hnpcc.REF.gruber.2003.137">Gruber &#x00026; Kohlmann 2003</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> MSH6 acts in a recessive manner at the cellular level where there is an absence of functional MSH6 protein in the tumor cells. This results from inactivation of both <i>MSH6</i> alleles in the tumor, which often occurs by the mechanism of <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a>.</p></div><div id="hnpcc.PMS2"><h4><i>PMS2</i></h4><p><b>Gene structure.</b>
<i>PMS2</i> comprises 15 exons encoding a protein of 862 amino acids. Multiple pseudogenes have been identified at 7p22, 7p12-13, 7q11, and 7q22 [<a class="bk_pop" href="#hnpcc.REF.nicolaides.1995.195">Nicolaides et al 1995</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1211/#hnpcc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Germline pathogenic variants in <i>PMS2</i> are rare [<a class="bk_pop" href="#hnpcc.REF.hendriks.2006.312">Hendriks et al 2006</a>]. Single-nucleotide variants and large <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> rearrangements have been reported. Studies that have included large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> testing have found that up to 20% of pathogenic variants may be large deletions. Large deletion testing of <i>PMS2</i> is technically difficult due to the numerous pseudogenes, and it presents significant challenges to laboratories trying to provide comprehensive large deletion testing for the whole gene. The currently available MLPA (multiplex ligation-dependent probe amplification) kit can detect deletions but does not clarify whether the deletion may be in one of the pseudogenes. Testing in coordination with a panel of reference samples can help determine whether deletions are clinically significant [<a class="bk_pop" href="#hnpcc.REF.vaughn.2011.1063">Vaughn et al 2011</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#hnpcc.MLH1"><i>MLH1</i></a>, <b>Normal gene product</b>.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>PMS2</i> acts in a recessive manner at the cellular level where there is an absence of functional <i>PMS2</i> protein in the tumor cells. This results from inactivation of both <i>PMS2</i> alleles in the tumor, which often occurs by the mechanism of <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a>.</p></div></div></div><div id="hnpcc.References"><h2 id="_hnpcc_References_">References</h2><div id="hnpcc.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF1">American College of Medical Genetics technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Available <a href="http://www.nature.com/gim/journal/v16/n1/full/gim2013166a.html" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2014. Accessed 1-14-19. [<a href="/pubmed/24310308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24310308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF2">American College of Medical Genetics/American Society of Human Genetics. Joint statement on genetic testing for colon cancer (pdf). Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111056/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2000. Accessed 1-14-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF3">American Gastroenterological Association. Medical position statement: hereditary colorectal cancer and genetic testing (pdf). Available <a href="https://www.gastrojournal.org/article/S0016-5085(01)90004-6/pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2001. Accessed 1-14-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF4">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <a href="http://jco.ascopubs.org/content/28/5/893.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 1-14-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF5">American Society of Colon and Rectal Surgeons. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (FAP and HNPCC). Available <a href="https://www.fascrs.org/sites/default/files/downloads/publication/identification_and_testing_of_a_patient_at_risk_for_dominantly_inherited_colorectal_cancer_supporting_documentation_1.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2003. Accessed 1-14-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF6">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 1-14-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.giardiello.2001.198">Giardiello FM, Brensinger JD, Petersen GM. American Gastroenterological Association technical review on hereditary colorectal cancer and genetic testing. <span><span class="ref-journal">Gastroenterology. </span>2001;<span class="ref-vol">121</span>:198–213.</span> [<a href="/pubmed/11438509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11438509</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.lu.2014.833">Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, Kohlmann W, Lindor NM, Mulvey TM, Robinson L, Rubinstein WS, Stoffel EM, Snyder C, Syngal S, Merrill JK, Wollins DS, Hughes KS, et al.  American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. <span><span class="ref-journal">J Clin Oncol. </span>2014;<span class="ref-vol">32</span>:833–40.</span> [<a href="/pmc/articles/PMC3940540/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3940540</span></a>] [<a href="/pubmed/24493721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24493721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF9">National Comprehensive Cancer Network. Guidelines for colorectal cancer screening. 2016.</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF10">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <a href="https://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 1-14-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.weissman.2012.484">Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S, Jasperson K, Kalady MF, Haidle JL, Lynch HT, Palaniappan S, Wise PE, Senter L. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. <span><span class="ref-journal">J Genet Couns. </span>2012;<span class="ref-vol">21</span>:484–93.</span> [<a href="/pubmed/22167527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22167527</span></a>]</div></li></ul></div><div id="hnpcc.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.aarnio.1997.551">Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Jarvinen HJ. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. <span><span class="ref-journal">Int J Cancer. </span>1997;<span class="ref-vol">74</span>:551–5.</span> [<a href="/pubmed/9355980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9355980</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.abdelrahman.2005.1542">Abdel-Rahman WM, Ollikainen M, Kariola R, Jarvinen HJ, Mecklin JP, Nystrom-Lahti M, Knuutila S, Peltomaki P. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. <span><span class="ref-journal">Oncogene. </span>2005;<span class="ref-vol">24</span>:1542–51.</span> [<a href="/pubmed/15674332" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15674332</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.anele.2017.528">Anele CC, Adegbola SO, Askari A, Rajendran A, Clark SK, Latchford A, Faiz OD. Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta-analysis. <span><span class="ref-journal">Colorectal Dis. </span>2017;<span class="ref-vol">19</span>:528–36.</span> [<a href="/pubmed/28407411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28407411</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.baglietto.2010.193">Baglietto L, Lindor NM, Dowty DM, Wagner A, Gomez Garcia EB, Vriends AH., Dutch Lynch Syndrome Study Group.  Cartwright NR, Barnetson RA, Farrington SM, Tenesa A, Hampel H, Buchanan D, Arnold S, Young J, Walsh MD, Jass J, Macrae F, Antill Y, Winship IM, Giles GG, Goldblatt J, Parry S, Suthers G, Leggett B, Butz M, Aronson M, Poynter JN, Baron JA, Le Marchand L, Haile R, Gallinger S, Hopper JL, Potter J, de la Chapelle A, Vasen HF, Dunlop MG, Thibodeau SN, Jenkins MA. Risks of Lynch syndrome cancers for MSH6 mutation carriers. <span><span class="ref-journal">J Natl Cancer Inst. </span>2010;<span class="ref-vol">102</span>:193–201.</span> [<a href="/pmc/articles/PMC2815724/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2815724</span></a>] [<a href="/pubmed/20028993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20028993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.bakry.2014.987">Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, Alharbi M, Shamvil A, Ben-Shachar S, Mistry M, Constantini S, Dvir R, Qaddoumi I, Gallinger S, Lerner-Ellis J, Pollett A, Stephens D, Kelies S, Chao E, Malkin D, Bouffet E, Hawkins C, Tabori U. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. <span><span class="ref-journal">Eur J Cancer. </span>2014;<span class="ref-vol">50</span>:987–96.</span> [<a href="/pubmed/24440087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24440087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.barrow.2009.141">Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. <span><span class="ref-journal">Clin Genet. </span>2009;<span class="ref-vol">75</span>:141–9.</span> [<a href="/pubmed/19215248" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19215248</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.bellido.2016.325">Bellido F, Pineda M, Aiza G, Vald&#x000e9;s-Mas R, Navarro M, Puente DA, Pons T, Gonz&#x000e1;lez S, Iglesias S, Darder E, Pi&#x000f1;ol V, Soto JL, Valencia A, Blanco I, Urioste M, Brunet J, L&#x000e1;zaro C, Capell&#x000e1; G, Puente XS, Valle L. POLE and POLD1 mutations in 529 kindreds with familial colorectal cancer and/or polyposis: a review of reported cases and recommendations for genetic testing and surveillance. <span><span class="ref-journal">Genet Med. </span>2016;<span class="ref-vol">18</span>:325–32.</span> [<a href="/pmc/articles/PMC4823640/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4823640</span></a>] [<a href="/pubmed/26133394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26133394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.bellizzi.2009.405">Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. <span><span class="ref-journal">Adv Anat Pathol. </span>2009;<span class="ref-vol">16</span>:405–17.</span> [<a href="/pubmed/19851131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19851131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.berends.2002.26">Berends MJ, Wu Y, Sijmons RH, Mensink RG, van der Sluis T, Hordijk-Hos JM, de Vries EG, Hollema H, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">70</span>:26–37.</span> [<a href="/pmc/articles/PMC384896/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC384896</span></a>] [<a href="/pubmed/11709755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11709755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.billingsley.2015.386">Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase e (POLE) mutations in endometrial cancer: clinical outcomes and implcations for Lynch syndrome testing. <span><span class="ref-journal">Cancer. </span>2015;<span class="ref-vol">121</span>:386–94.</span> [<a href="/pmc/articles/PMC4304930/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4304930</span></a>] [<a href="/pubmed/25224212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25224212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.bisgaard.2003.56">Bisgaard ML, Bernstein I. HNPCC mutation rate (published abstract). <span><span class="ref-journal">Familial Cancer. </span>2003;<span class="ref-vol">2</span>:56.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.bisschops.2017.342">Bisschops R, Tejpar S, Willekens H, Hertogh GD, Van Cutsem E. Virtual chromoenscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial. <span><span class="ref-journal">Endoscopy. </span>2017;<span class="ref-vol">49</span>:342–50.</span> [<a href="/pubmed/28107763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28107763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.bonadona.2011.2304">Bonadona V, Bona&#x000ef;ti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Nogu&#x000e8;s C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Fr&#x000e9;bourg T, Sobol H, Lasset C, Bona&#x000ef;ti-Pelli&#x000e9; C., French Cancer Genetics Network.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. <span><span class="ref-journal">JAMA. </span>2011;<span class="ref-vol">305</span>:2304–10.</span> [<a href="/pubmed/21642682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21642682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.bouzourene.2010.167">Bouzourene H, Hutter P, Losi L, Martin P, Benhattar J. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. <span><span class="ref-journal">Fam Cancer. </span>2010;<span class="ref-vol">9</span>:167–72.</span> [<a href="/pubmed/19949877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19949877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.burn.2008.2567">Burn J, Bishop DT, Mecklin JP, Macrae F, M&#x000f6;slein G, Olschwang S, Bisgaard ML, Ramesar R, Eccles D, Maher ER, Bertario L, Jarvinen HJ, Lindblom A, Evans DG, Lubinski J, Morrison PJ, Ho JW, Vasen HF, Side L, Thomas HJ, Scott RJ, Dunlop M, Barker G, Elliott F, Jass JR, Fodde R, Lynch HT, Mathers JC. CAPP2 Investigators. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">359</span>:2567–78.</span> [<a href="/pubmed/19073976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19073976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.burn.2011.2081">Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT. CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. <span><span class="ref-journal">Lancet. </span>2011;<span class="ref-vol">378</span>:2081–7.</span> [<a href="/pmc/articles/PMC3243929/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3243929</span></a>] [<a href="/pubmed/22036019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22036019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.capelle.2010.487">Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, Vasen HF, Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. <span><span class="ref-journal">Gastroenterology. </span>2010;<span class="ref-vol">138</span>:487–92.</span> [<a href="/pubmed/19900449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19900449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.chadwick.2001.461">Chadwick RB, Pyatt RE, Niemann TH, Richards SK, Johnson CK, Stevens MW, Meek JE, Hampel H, Prior TW, de la Chapelle A. Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma. <span><span class="ref-journal">J Med Genet. </span>2001;<span class="ref-vol">38</span>:461–6.</span> [<a href="/pmc/articles/PMC1757178/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1757178</span></a>] [<a href="/pubmed/11474654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11474654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.chen.2006.1479">Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Watson P, Gruber SB, Euhus D, Kinzler KW, Jass J, Gallinger S, Lindor NM, Casey G, Ellis N, Giardiello FM, Offit K, Parmigiani G. Colon Cancer Family Registry. Prediction of germline mutations and cancer risk in the Lynch syndrome. <span><span class="ref-journal">JAMA. </span>2006;<span class="ref-vol">296</span>:1479–87.</span> [<a href="/pmc/articles/PMC2538673/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2538673</span></a>] [<a href="/pubmed/17003396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17003396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.cunningham.2001.780">Cunningham JM, Kim CY, Christensen ER, Tester DJ, Parc Y, Burgart LJ, Halling KC, McDonnell SK, Schaid DJ, Walsh Vockley C, Kubly V, Nelson H, Michels VV, Thibodeau SN. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:780–90.</span> [<a href="/pmc/articles/PMC1226064/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1226064</span></a>] [<a href="/pubmed/11524701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11524701</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.dashti.2015.61">Dashti SG, Chau R, Ouakrim DA, Buchanan DD, Clendenning M, Young JP, Winship IM, Arnold J, Ahnen DJ, Haile RW, Casey G, Gallinger S, Thibodeau SN, Lindor NM, Le Marchand L, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. <span><span class="ref-journal">JAMA. </span>2015;<span class="ref-vol">314</span>:61–71.</span> [<a href="/pmc/articles/PMC4688894/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4688894</span></a>] [<a href="/pubmed/26151267" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26151267</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.den_bakker.2003.297">den Bakker MA, Seynaeve C, Kliffen M, Dinjens WN. Microsatellite instability in a pleomorphic rhabdomyosarcoma in a patient with hereditary non-polyposis colorectal cancer. <span><span class="ref-journal">Histopathology. </span>2003;<span class="ref-vol">43</span>:297–9.</span> [<a href="/pubmed/12940783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12940783</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.doveedwin.2002.1708">Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF, Thomas HJ. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. <span><span class="ref-journal">Cancer. </span>2002;<span class="ref-vol">94</span>:1708–12.</span> [<a href="/pubmed/11920532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11920532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.durno.2010.2449">Durno CA, Holter S, Sherman PM, Gallinger S. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. <span><span class="ref-journal">Am J Gastroenterol. </span>2010;<span class="ref-vol">105</span>:2449–56.</span> [<a href="/pubmed/20531397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20531397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.egapp.2009.35">EGAPP. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.  Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. <span><span class="ref-journal">Genet Med. </span>2009;<span class="ref-vol">11</span>:35–41.</span> [<a href="/pmc/articles/PMC2743612/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2743612</span></a>] [<a href="/pubmed/19125126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19125126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.entius.2000.1784">Entius MM, Keller JJ, Drillenburg P, Kuypers KC, Giardiello FM, Offerhaus GJ. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. <span><span class="ref-journal">Clin Cancer Res. </span>2000;<span class="ref-vol">6</span>:1784–9.</span> [<a href="/pubmed/10815898" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10815898</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.evans.2009.593">Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, D&#x000f8;rum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. <span><span class="ref-journal">J Med Genet. </span>2009;<span class="ref-vol">46</span>:593–7.</span> [<a href="/pubmed/18413372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18413372</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.fishel.1993.1027">Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. <span><span class="ref-journal">Cell. </span>1993;<span class="ref-vol">75</span>:1027–38.</span> [<a href="/pubmed/8252616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8252616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.gargiulo.2009.547">Gargiulo S, Torrini M, Ollila S, Nasti S, Pastorino L, Cusano R, Bonelli L, Battistuzzi L, Mastracci L, Bruno W, Savarino V, Sciallero S, Borgonovo G, Nystr&#x000f6;m M, Bianchi-Scarr&#x000e0; G, Mareni C, Ghiorzo P. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. <span><span class="ref-journal">Fam Cancer. </span>2009;<span class="ref-vol">8</span>:547–53.</span> [<a href="/pubmed/19728162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19728162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.giardiello.2014.1159">Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. <span><span class="ref-journal">Am J Gastroenterol. </span>2014;<span class="ref-vol">109</span>:1159–79.</span> [<a href="/pubmed/25070057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25070057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.goel.2011.869">Goel A, Nguyen TP, Leung HC, Nagasaka T, Rhees J, Hotchkiss E, Arnold M, Banerji P, Koi M, Kwok CT, Packham D, Lipton L, Boland CR, Ward RL, Hitchins MP. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. <span><span class="ref-journal">Int J Cancer. </span>2011;<span class="ref-vol">128</span>:869–78.</span> [<a href="/pmc/articles/PMC3794437/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3794437</span></a>] [<a href="/pubmed/20473912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20473912</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.goodenberger.2016.13">Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, Win AK, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, Lu KH, Thibodeau S, Lindor NM. PMS2 monoallelic mutation carriers: the known unknown. <span><span class="ref-journal">Genet Med. </span>2016;<span class="ref-vol">18</span>:13–9.</span> [<a href="/pmc/articles/PMC4834863/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4834863</span></a>] [<a href="/pubmed/25856668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25856668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.gruber.2003.137">Gruber SB, Kohlmann W. The genetics of hereditary non-polyposis colorectal cancer. <span><span class="ref-journal">J Natl Compr Canc Netw. </span>2003;<span class="ref-vol">1</span>:137–44.</span> [<a href="/pubmed/19764157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19764157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.guilford.1999.249">Guilford PJ, Hopkins JB, Grady WM, Markowitz SD, Willis J, Lynch H, Rajput A, Wiesner GL, Lindor NM, Burgart LJ, Toro TT, Lee D, Limacher JM, Shaw DW, Findlay MP, Reeve AE. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">14</span>:249–55.</span> [<a href="/pubmed/10477433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10477433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.hamilton.1995.839">Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, Krush AJ, Berk T, Cohen Z, Tetu B, Burger PC, Wood PA, Taqi F, Booker SV, Petersen GM, Offerhaus GJA, Tersmette AC, Giardiello FM, Vogelstein V, Kinzler KW. The molecular basis of Turcot's syndrome. <span><span class="ref-journal">N Engl J Med. </span>1995;<span class="ref-vol">332</span>:839–47.</span> [<a href="/pubmed/7661930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7661930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.haraldsdottir.2014.553">Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM. Prostate cancer incidence in males with Lynch syndrome. <span><span class="ref-journal">Genet Med. </span>2014;<span class="ref-vol">16</span>:553–7.</span> [<a href="/pmc/articles/PMC4289599/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4289599</span></a>] [<a href="/pubmed/24434690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24434690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.hegde.2014.101">Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A., Working Group of the American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee.  ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). <span><span class="ref-journal">Genet Med. </span>2014;<span class="ref-vol">16</span>:101–16.</span> [<a href="/pubmed/24310308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24310308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.hendriks.2006.312">Hendriks YM, Jagmohan-Changur S, van der Klift HM, Morreau H, van Puijenbroek M, Tops C, van Os T, Wagner A, Ausems MG, Gomez E, Breuning MH, Brocker-Vriends AH, Vasen HF, Wijnen JT. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). <span><span class="ref-journal">Gastroenterology. </span>2006;<span class="ref-vol">130</span>:312–22.</span> [<a href="/pubmed/16472587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16472587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.h_neburg.2009.316">H&#x000fc;neburg R, Lammert F, Rabe C, Rahner N, Kahl P, B&#x000fc;ttner R, Propping P, Sauerbruch T, Lamberti C. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. <span><span class="ref-journal">Endoscopy. </span>2009;<span class="ref-vol">41</span>:316–22.</span> [<a href="/pubmed/19340735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19340735</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.j_rvinen.2009.4793">J&#x000e4;rvinen HJ, Renkonen-Sinisalo L, Akt&#x000e1;n-Coll&#x000e1;n K, Peltom&#x000e4;ki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation negative family members. <span><span class="ref-journal">J Clin Oncol. </span>2009;<span class="ref-vol">27</span>:4793–7.</span> [<a href="/pubmed/19720893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19720893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.kastrinos.2009.1790">Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S. Risk of pancreatic cancer in families with Lynch syndrome. <span><span class="ref-journal">JAMA. </span>2009;<span class="ref-vol">302</span>:1790–5.</span> [<a href="/pmc/articles/PMC4091624/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4091624</span></a>] [<a href="/pubmed/19861671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19861671</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.kastrinos.2015">Kastrinos F, Ojha RP, Leenen C, Alvero C, Mercado RC, Balma&#x000f1;a J, Valenzuela I, Balaguer F, Green R, Lindor NM, Thibodeau SN, Newcomb P, Win AK, Jenkins M, Buchanan DD, Bertario L, Sala P, Hampel H, Syngal S, Steyerberg EW. Lynch syndrome prediction model validation study group. Comparison of prediction models for Lynch syndrome among individuals with colorectal cancer. <span><span class="ref-journal">J Natl Cancer Inst. </span>2015;<span class="ref-vol">108</span>(2)</span> [<a href="/pmc/articles/PMC4862416/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4862416</span></a>] [<a href="/pubmed/26582061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26582061</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.kastrinos.2011.73">Kastrinos F, Steyerberg EW, Mercado R, Balmana J, Holter S, Gallinger S, Siegnund KD, Church JM, Jenkins MA, Lindor NM, Thibodeau SN, Burbidge LA, Wenstrup RJ, Syngal S. The PREMM(1,2,6) Model predicts risk of MLH1, MSH2, and MSH6 germline mutations. <span><span class="ref-journal">Gastroenterology. </span>2011;<span class="ref-vol">140</span>:73–81.</span> [<a href="/pmc/articles/PMC3125673/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3125673</span></a>] [<a href="/pubmed/20727894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20727894</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.kawakami.2015.30">Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. <span><span class="ref-journal">Curr Treat Options Oncol. </span>2015;<span class="ref-vol">16</span>:30.</span> [<a href="/pmc/articles/PMC4594190/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4594190</span></a>] [<a href="/pubmed/26031544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26031544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.kempers.2011.49">Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E, Morak M, Kloor M, B&#x000fc;ttner R, Verwiel ET, van Krieken JH, Nagtegaal ID, Goossens M, van der Post RS, Niessen RC, Sijmons RH, Kluijt I, Hogervorst FB, Leter EM, Gille JJ, Aalfs CM, Redeker EJ, Hes FJ, Tops CM, van Nesselrooij BP, van Gijn ME, G&#x000f3;mez Garc&#x000ed;a EB, Eccles DM, Bunyan DJ, Syngal S, Stoffel EM, Culver JO, Palomares MR, Graham T, Velsher L, Papp J, Ol&#x000e1;h E, Chan TL, Leung SY, van Kessel AG, Kiemeney LA, Hoogerbrugge N, Ligtenberg MJ. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. <span><span class="ref-journal">Lancet Oncol. </span>2011;<span class="ref-vol">12</span>:49–55.</span> [<a href="/pmc/articles/PMC3670774/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3670774</span></a>] [<a href="/pubmed/21145788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21145788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.kowalski.1997.219">Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>1997;<span class="ref-vol">18</span>:219–27.</span> [<a href="/pubmed/9071575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9071575</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.kuiper.2011.407">Kuiper RP, Vissers LE, Venkatachalam R, Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC, Hogervorst FB, Gille JJ, Redeker B, Tops CM, van Gijn ME, van den Ouweland AM, Rahner N, Steinke V, Kahl P, Holinski-Feder E, Morak M, Kloor M, Stemmler S, Betz B, Hutter P, Bunyan DJ, Syngal S, Culver JO, Graham T, Chan TL, Nagtegaal ID, van Krieken JH, Schackert HK, Hoogerbrugge N, van Kessel AG, Ligtenberg MJ. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. <span><span class="ref-journal">Hum Mutat. </span>2011;<span class="ref-vol">32</span>:407–14.</span> [<a href="/pubmed/21309036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21309036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.ladabaum.2011.69">Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA. Strategies to identify Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. <span><span class="ref-journal">Ann Intern Med. </span>2011;<span class="ref-vol">155</span>:69–79.</span> [<a href="/pmc/articles/PMC3793257/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3793257</span></a>] [<a href="/pubmed/21768580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21768580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.ligtenberg.2009.112">Ligtenberg MJL, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. <span><span class="ref-journal">Nat Genet. </span>2009;<span class="ref-vol">41</span>:112–7.</span> [<a href="/pubmed/19098912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19098912</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.lindor.2005.1979">Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, Gallinger S, Bapat B, Aronson M, Hopper J, Jass J, LeMarchand L, Grove J, Potter J, Newcomb P, Terdiman JP, Conrad P, Moslein G, Goldberg R, Ziogas A, Anton-Culver H, de Andrade M, Siegmund K, Thibodeau SN, Boardman LA, Seminara D. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. <span><span class="ref-journal">JAMA. </span>2005;<span class="ref-vol">293</span>:1979–85.</span> [<a href="/pmc/articles/PMC2933042/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2933042</span></a>] [<a href="/pubmed/15855431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15855431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.lu.2005.569">Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. <span><span class="ref-journal">Obstet Gynecol. </span>2005;<span class="ref-vol">105</span>:569–74.</span> [<a href="/pubmed/15738026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15738026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.lu.2013.774">Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. <span><span class="ref-journal">Cancer Prev Res (Phila). </span>2013;<span class="ref-vol">6</span>:774–81.</span> [<a href="/pmc/articles/PMC3737517/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3737517</span></a>] [<a href="/pubmed/23639481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23639481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.lu.1998.17">Lu SL, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, Yuasa Y. HNPCC associated with germline mutation in the TGF-beta type II receptor gene. <span><span class="ref-journal">Nat Genet. </span>1998;<span class="ref-vol">19</span>:17–8.</span> [<a href="/pubmed/9590282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9590282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.machin.2002.415">Machin P, Catasus L, Pons C, Munoz J, Conde-Zurita JM, Balmana J, Barnadas M, Marti RM, Prat J, Matias-Guiu X. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. <span><span class="ref-journal">J Cutan Pathol. </span>2002;<span class="ref-vol">29</span>:415–20.</span> [<a href="/pubmed/12139636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12139636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.mange.2015.421">Mange S, Bellcross C, Cragun D, Duquette D, Gorman L, Hampel H, Jasperson J. Creation of a network to promote universal screening for Lynch syndrome: the Lynch syndrome screening network. <span><span class="ref-journal">J Genet Couns. </span>2015;<span class="ref-vol">24</span>:421–7.</span> [<a href="/pmc/articles/PMC4547789/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4547789</span></a>] [<a href="/pubmed/25220566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25220566</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.maxwell.2001.417">Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. <span><span class="ref-journal">Obstet Gynecol. </span>2001;<span class="ref-vol">97</span>:417–22.</span> [<a href="/pubmed/11239648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11239648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.misago.2000.155">Misago N, Narisawa Y. Sebaceous neoplasms in Muir-Torre syndrome. <span><span class="ref-journal">Am J Dermatopathol. </span>2000;<span class="ref-vol">22</span>:155–61.</span> [<a href="/pubmed/10770437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10770437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.miyaki.1997.271">Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. <span><span class="ref-journal">Nat Genet. </span>1997;<span class="ref-vol">17</span>:271–2.</span> [<a href="/pubmed/9354786" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9354786</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.mork.2015.3544">Mork ME, You YN, Ying J, Bannon SA, Lynch PM, Rodriguez-Bigas MA, Vilar E. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. <span><span class="ref-journal">J Clin Oncol. </span>2015;<span class="ref-vol">33</span>:3544–9.</span> [<a href="/pmc/articles/PMC4979241/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4979241</span></a>] [<a href="/pubmed/26195711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26195711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.muellerkoch.2005.1733">Mueller-Koch Y, Vogelsang H, Kopp R, Lohse P, Keller G, Aust D, Muders M, Gross M, Daum J, Schiemann U, Grabowski M, Scholz M, Kerker B, Becker I, Henke G, Holinski-Feder E. Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. <span><span class="ref-journal">Gut. </span>2005;<span class="ref-vol">54</span>:1733–40.</span> [<a href="/pmc/articles/PMC1774771/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1774771</span></a>] [<a href="/pubmed/15955785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15955785</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF72">NCCN. National Comprehensive Cancer Network guidelines for colorectal cancer screening. 2016.</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.nicolaides.1995.195">Nicolaides NC, Carter KC, Shell BK, Papadopoulos N, Vogelstein B, Kinzler KW. Genomic organization of the human PMS2 gene family. <span><span class="ref-journal">Genomics. </span>1995;<span class="ref-vol">30</span>:195–206.</span> [<a href="/pubmed/8586419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8586419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.niessen.2009.737">Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, de Groote ML, Dijkhuizen T, Olderode-Berends MJ, Hollema H, Kleibeuker JH, Sijmons RH. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2009;<span class="ref-vol">48</span>:737–44.</span> [<a href="/pubmed/19455606" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19455606</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.nilbert.2009.209">Nilbert M, Therkildsen C, Nissen A, Akerman M, Bernstein I. Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. <span><span class="ref-journal">Fam Cancer. </span>2009;<span class="ref-vol">8</span>:209–13.</span> [<a href="/pubmed/19130300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19130300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.obermair.2010.2678">Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, Parry S, Hopper JL, Haile R, Jenkins MA. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. <span><span class="ref-journal">Int J Cancer. </span>2010;<span class="ref-vol">127</span>:2678–84.</span> [<a href="/pmc/articles/PMC2947566/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2947566</span></a>] [<a href="/pubmed/20533284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20533284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.pande.2010.1331">Pande M, Lynch PM, Hopper JL, Jenkins MA, Gallinger S, Haile RW, LeMarchand L, Lindor NM, Campbell PT, Newcomb PA, Potter JD, Baron JA, Frazier ML, Amos CI. Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:1331–9.</span> [<a href="/pmc/articles/PMC2822883/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2822883</span></a>] [<a href="/pubmed/20145170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20145170</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.park.2000.2994">Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. <span><span class="ref-journal">Clin Cancer Res. </span>2000;<span class="ref-vol">6</span>:2994–8.</span> [<a href="/pubmed/10955776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10955776</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.peltom_ki.2003.1174">Peltom&#x000e4;ki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. <span><span class="ref-journal">J Clin Oncol. </span>2003;<span class="ref-vol">21</span>:1174–9.</span> [<a href="/pubmed/12637487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12637487</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.peltom_ki.2004.269">Peltom&#x000e4;ki P, Vasen H. Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database. <span><span class="ref-journal">Dis Markers. </span>2004;<span class="ref-vol">20</span>:269–76.</span> [<a href="/pmc/articles/PMC3839397/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3839397</span></a>] [<a href="/pubmed/15528792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15528792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.ponti.2006.2302">Ponti G, Losi L, Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellancani G, Seidenari S. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. <span><span class="ref-journal">J Invest Dermatol. </span>2006;<span class="ref-vol">126</span>:2302–7.</span> [<a href="/pubmed/16826164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16826164</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.pritchard.2016.443">Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. <span><span class="ref-journal">N Engl J Med. </span>2016;<span class="ref-vol">375</span>:443–53.</span> [<a href="/pmc/articles/PMC4986616/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4986616</span></a>] [<a href="/pubmed/27433846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27433846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.rabban.2014.793">Rabban JT, Calkins SM, Karnezis AN, Grenert JP, Blanco A, Crawford B, Chen LM. Association of Tumor Morphology With Mismatch-repair Protein Status in Older Endometrial Cancer Patients: Implications for Universal Versus Selective Screening Strategies for Lynch Syndrome. <span><span class="ref-journal">Am J Surg Pathol. </span>2014;<span class="ref-vol">38</span>:793–800.</span> [<a href="/pubmed/24503759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24503759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.rahmi.2015.288">Rahmi G, Lecomte T, Malka D, Maniere T, Le Rhun M, Guimbaud R, Lapalus MG, Le Sidaner A, Moussata D, Caron O, Barbieux JP, Gaudric M, Coron E, Barange K, Ponchon T, Sautereau D, Samaha E, Saurin JC, Chaussade S, Laurent-Puig P, Chatellier G, Cellier C. Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study. <span><span class="ref-journal">Am J Gastroenterol. </span>2015;<span class="ref-vol">110</span>:288–98.</span> [<a href="/pubmed/25601014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25601014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.raymond.2013a.3012">Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, Hammer GD, Stoffel EM, Greenson JK, Giordano TJ, Else T. Adrenocortical carcinoma is a lynch syndrome-associated cancer. <span><span class="ref-journal">J Clin Oncol. </span>2013a;<span class="ref-vol">31</span>:3012–8.</span> [<a href="/pmc/articles/PMC3739861/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3739861</span></a>] [<a href="/pubmed/23752102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23752102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.raymond.2013b.1713">Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, Syngal S, Cooney KA, Gruber SB. Elevated risk of prostate cancer among men with Lynch syndrome. <span><span class="ref-journal">J Clin Oncol. </span>2013b;<span class="ref-vol">31</span>:1713–8.</span> [<a href="/pmc/articles/PMC3641694/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3641694</span></a>] [<a href="/pubmed/23530095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23530095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.renkonensinisalo.2002.574">Renkonen-Sinisalo L, Sipponen P, Aarnio M, Julkunen R, Aaltonen LA, Sarna S, Jarvinen HJ, Mecklin JP. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. <span><span class="ref-journal">Scand J Gastroenterol. </span>2002;<span class="ref-vol">37</span>:574–7.</span> [<a href="/pubmed/12059060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12059060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.rodriguezbigas.1998.240">Rodriguez-Bigas MA, Vasen HF, Lynch HT, Watson P, Myrhoj T, Jarvinen HJ, Mecklin JP, Macrae F, St John DJ, Bertario L, Fidalgo P, Madlensky L, Rozen P. Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC. <span><span class="ref-journal">Cancer. </span>1998;<span class="ref-vol">83</span>:240–4.</span> [<a href="/pubmed/9669805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9669805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.rothwell.2011.31">Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term randomized trials. <span><span class="ref-journal">Lancet. </span>2011;<span class="ref-vol">377</span>:31–41.</span> [<a href="/pubmed/21144578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21144578</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.ryan.2014.437">Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. <span><span class="ref-journal">Cancer Epidemiol Biomarkers Prev. </span>2014;<span class="ref-vol">23</span>:437–49.</span> [<a href="/pubmed/24425144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24425144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.schulmann.2005.590">Schulmann K, Brasch FE, Kunstmann E, Engel C, Pagenstecher C, Vogelsang H, Kruger S, Vogel T, Knaebel HP, Ruschoff J, Hahn SA, Knebel-Doeberitz MV, Moeslein G, Meltzer SJ, Schackert HK, Tympner C, Mangold E, Schmiegel W. HNPCC-associated small bowel cancer: clinical and molecular characteristics. <span><span class="ref-journal">Gastroenterology. </span>2005;<span class="ref-vol">128</span>:590–9.</span> [<a href="/pubmed/15765394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15765394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.senter.2008.419">Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, Young J, Winship I, Dowty JG, White DM, Hopper JL, Baglietto L, Jenkins MA, de la Chapelle A. The clinical phenotype of Lynch syndrome due to germline PMS2 mutations. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:419–28.</span> [<a href="/pmc/articles/PMC2759321/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2759321</span></a>] [<a href="/pubmed/18602922" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18602922</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.sijmons.2000.353">Sijmons R, Hofstra R, Hollema H, Mensink R, van der Hout A, Hoekstra H, Kleibeuker J, Molenaar W, Wijnen J, Fodde R, Vasen H, Buys C. Inclusion of malignant fibrous histiocytoma in the tumour spectrum associated with hereditary non-polyposis colorectal cancer. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2000;<span class="ref-vol">29</span>:353–5.</span> [<a href="/pubmed/11066081" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11066081</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.sivagnanam.2010.222">Sivagnanam M, Schaible T, Szigeti R, Byrd RH, Finegold MJ, Ranganathan S, Gopalakrishna GS, Tatevian N, Kellermayer R. Further evidence for EpCAM as the gene for congenital tufting enteropathy. <span><span class="ref-journal">Am J Med Genet. </span>2010;<span class="ref-vol">152A</span>:222–4.</span> [<a href="/pmc/articles/PMC6691968/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6691968</span></a>] [<a href="/pubmed/20034091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20034091</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.smith.2016.250">Smith MJ, Urquhart JE, Harkness EF, Miles EK, Bowers NL, Byers HJ, Bulman M, Gokhale C, Wallace AJ, Newman WG, Evans DG. The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes. <span><span class="ref-journal">Hum Mutat. </span>2016;<span class="ref-vol">37</span>:250–6.</span> [<a href="/pubmed/26615784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26615784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.south.2008.277">South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. <span><span class="ref-journal">J Natl Cancer Inst. </span>2008;<span class="ref-vol">100</span>:277–81.</span> [<a href="/pubmed/18270343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18270343</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.stoffel.2008.470">Stoffel EM, Turgeon DK, Stockwell DH, Zhao L, Normolle DP, Tuck MK, Bresalier RS, Marcon NE, Baron JA, Ruffin MT, Brenner DE, Syngal S., Great Lakes-New England Clinical Epidemiology and Validation Center of the Early Detection Research Network.  Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). <span><span class="ref-journal">Cancer Prev Res (Phila). </span>2008;<span class="ref-vol">1</span>:470–5.</span> [<a href="/pmc/articles/PMC2671076/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2671076</span></a>] [<a href="/pubmed/19138994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19138994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.suzui.1998.126">Suzui M, Yoshimi N, Hara A, Morishita Y, Tanaka T, Mori H. Genetic alterations in a patient with Turcot's syndrome. <span><span class="ref-journal">Pathol Int. </span>1998;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pubmed/9589476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9589476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.tutlewska.2013.9">Tutlewska K, Lubinski J, Kurzawski G. Germlie deletions in the EPCAM gene as a cause of Lynch syndrome. <span><span class="ref-journal">Hered Cancer Clin Pract. </span>2013;<span class="ref-vol">11</span>:9.</span> [<a href="/pmc/articles/PMC3765447/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3765447</span></a>] [<a href="/pubmed/23938213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23938213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.van_der_klift.2010.578">van der Klift HM, Tops CM, Bik EC, Boogaard MW, Borgstein AM, Hansson KB, Ausems MG, Gomez Garcia E, Green A, Hes FJ, Izatt L, van Hest LP, Alonso AM, Vriends AH, Wagner A, van Zelst-Stams WA, Vasen HF, Morreau H, Devilee P, Wijnen JT. Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:578–87.</span> [<a href="/pubmed/20186688" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20186688</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.van_der_klift.2005.123">van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, Kohonen-Corish M, Vasen H, Oliani C, Barana D, Moller P, Delozier-Blanchet C, Hutter P, Foulkes W, Lynch H, Burn J, Moslein G, Fodde R. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2005;<span class="ref-vol">44</span>:123–38.</span> [<a href="/pubmed/15942939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15942939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.van_der_post.2010.464">van der Post RS, Kiemeny LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Schaap L, Kets CM, van Krieken JH, Hoogerbrugge N. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. <span><span class="ref-journal">J Med Genet. </span>2010;<span class="ref-vol">47</span>:464–70.</span> [<a href="/pmc/articles/PMC2991077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2991077</span></a>] [<a href="/pubmed/20591884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20591884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.vasen.2013.812">Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, M&#x000f8;ller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, J&#x000e4;rvinen HJ, M&#x000f6;slein G., Mallorca group.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. <span><span class="ref-journal">Gut. </span>2013;<span class="ref-vol">62</span>:812–23.</span> [<a href="/pmc/articles/PMC3647358/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3647358</span></a>] [<a href="/pubmed/23408351" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23408351</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.vaughn.2011.1063">Vaughn CP, Hart KJ, Samowitz WS, Swensen JJ. Avoidance of pseudogene interfence in the detection of 3' deletions in PMS2. <span><span class="ref-journal">Hum Mutat. </span>2011;<span class="ref-vol">32</span>:1063–71.</span> [<a href="/pubmed/21618646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21618646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.vaughn.2010.588">Vaughn CP, Robles J, Swensen JJ, Miller CE, Lyon E, Mao R, Bayrak-Toydemir P, Samowitz WS. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:588–93.</span> [<a href="/pubmed/20205264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20205264</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.watson.2001.223">Watson P, Butzow R, Lynch HT, Mecklin JP, Jarvinen HJ, Vasen HF, Madlensky L, Fidalgo P, Bernstein I. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. <span><span class="ref-journal">Gynecol Oncol. </span>2001;<span class="ref-vol">82</span>:223–8.</span> [<a href="/pubmed/11531271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11531271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.watson.2008.444">Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, J&#x000e4;rvinen HJ, Myrh&#x000f8;j T, Sunde L, Wijnen JT, Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. <span><span class="ref-journal">Int J Cancer. </span>2008;<span class="ref-vol">123</span>:444–9.</span> [<a href="/pmc/articles/PMC2627772/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2627772</span></a>] [<a href="/pubmed/18398828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18398828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.weren.2018.135">Weren RD, Ligteberg MJ, Geurts van Kessel A, De Voer RM, Hoogerbrugge N, Kuiper RP. NTHL1 and MUTYH polyposis syndromes: two sides of the same coin? <span><span class="ref-journal">J Pathol. </span>2018;<span class="ref-vol">244</span>:135–42.</span> [<a href="/pubmed/29105096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29105096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.wimmer.2012">Wimmer K. Relationship between NF1 and constitutive mismatch repair deficiency. In Upadhyaya M, Cooper DN, eds. Neurofibromatosis Type 1. Berlin, Germany: Springer-Verlag; 2012:235-51.</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.wimmer.2008.105">Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? <span><span class="ref-journal">Hum Genet. </span>2008;<span class="ref-vol">124</span>:105–22.</span> [<a href="/pubmed/18709565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18709565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.win.2013a.785">Win AK, Macinnis RJ, Dowty JG, Jenkins MA. Criteria and prediction models for mismatch repair gene mutations: a review. <span><span class="ref-journal">J Med Genet. </span>2013a;<span class="ref-vol">50</span>:785–93.</span> [<a href="/pubmed/23956446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23956446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.win.2012.958">Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, Buchanan DD, Clendenning M, Giles GG, Winship I, Macrae FA, Goldblatt J, Southey MC, Arnold J, Thibodeau SN, Gunawardena SR, Bapat B, Baron JA, Casey G, Gallinger S, Le Marchand L, Newcomb PA, Haile RW, Hopper JL, Jenkins MA. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. <span><span class="ref-journal">J Clin Oncol. </span>2012;<span class="ref-vol">30</span>:958–64.</span> [<a href="/pmc/articles/PMC3341109/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3341109</span></a>] [<a href="/pubmed/22331944" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22331944</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.win.b">Win KW, Lindor NM, Jenkins MA. Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Research. 2013b;15:R27. Available <a href="https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3405" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. Accessed 1-14-19. [<a href="/pmc/articles/PMC3672741/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3672741</span></a>] [<a href="/pubmed/23510156" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23510156</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.wu.1999.1291">Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, van Der Zee AG, Hollema H, Kleibeuker JH, Buys CH, Hofstra RM. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">65</span>:1291–8.</span> [<a href="/pmc/articles/PMC1288281/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288281</span></a>] [<a href="/pubmed/10521294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10521294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hnpcc.REF.yurgelun.2017.1086">Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer susceptibility gene mutations in individuals with colorectal cancer. <span><span class="ref-journal">J Clin Oncol. </span>2017;<span class="ref-vol">35</span>:1086–95.</span> [<a href="/pmc/articles/PMC5455355/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5455355</span></a>] [<a href="/pubmed/28135145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28135145</span></a>]</div></li></ul></div></div><div id="hnpcc.Chapter_Notes"><h2 id="_hnpcc_Chapter_Notes_">Chapter Notes</h2><div id="hnpcc.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 April 2018 (sw) Revision: Tumor testing table added (<a class="figpopup" href="/books/NBK1211/table/hnpcc.T.summary_of_tumor_tissue_test_res/?report=objectonly" target="object" rid-figpopup="fighnpccTsummaryoftumortissuetestres" rid-ob="figobhnpccTsummaryoftumortissuetestres">Table 2</a>)</div></li><li class="half_rhythm"><div>1 February 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 May 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 September 2012 (cd) Revision: Multigene panels for Lynch syndrome (hereditary non-polyposis colon cancer) available clinically</div></li><li class="half_rhythm"><div>11 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>29 November 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 February 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>18 April 2003 (sg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1211</span><span class="label">PMID: <a href="/pubmed/20301390" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301390</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/x-lpd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/lpi/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1211&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1211/?report=reader">PubReader</a></li><li><a href="/books/NBK1211/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1211" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1211" style="display:none" title="Cite this Page"><div class="bk_tt">Kohlmann W, Gruber SB. Lynch Syndrome. 2004 Feb 5 [Updated 2018 Apr 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1211/pdf/Bookshelf_NBK1211.pdf">PDF version of this page</a> (629K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hnpcc.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hnpcc.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hnpcc.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hnpcc.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hnpcc.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hnpcc.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hnpcc.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hnpcc.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hnpcc.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hnpcc.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hnpcc.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2033[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">EP300</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5378[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PMS1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4893[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NRAS</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=207[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AKT1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1630[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DCC</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7157[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TP53</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5395[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PMS2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=10395[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DLC1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=324[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">APC</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=701[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BUB1B</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4292[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MLH1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6714[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SRC</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4072[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">EPCAM</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2261[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FGFR3</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1499[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CTNNB1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=201163[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FLCN</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8313[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AXIN2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4436[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MSH2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5290[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PIK3CA</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=699[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BUB1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2956[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MSH6</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1479470" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1479470" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1479470" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1479470" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29107668" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.</a><span class="source">[Hum Pathol. 2017]</span><div class="brieflinkpop offscreen_noflow">Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dillon JL, Gonzalez JL, DeMars L, Bloch KJ, Tafe LJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Pathol. 2017 Dec; 70:121-128. Epub 2017 Oct 28.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10388011" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.</a><span class="source">[Oncologist. 1996]</span><div class="brieflinkpop offscreen_noflow">Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Piver MS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Oncologist. 1996; 1(5):326-330. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301519" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">APC</i>-Associated Polyposis Conditions</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">APC</i>-Associated Polyposis Conditions<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Jasperson KW, Patel SG, Ahnen DJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301642" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Juvenile Polyposis Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Juvenile Polyposis Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Larsen Haidle J, Howe JR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301488" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schneider K, Zelley K, Nichols KE, Garber J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301390" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301390" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041780dd21425a252ecd55">Lynch Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Lynch Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:14:24-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE895FF8E040C5E10000000005990257&amp;ncbi_session=CE895FF8E04177F1_1433SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1211%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1211&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1211/&amp;ncbi_pagename=Lynch Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE895FF8E04177F1_1433SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>